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Povzetek 
Parkinsonova bolezen (PB) je nevrodegenerativna motnja, ki se pojavi po 60. 
letu starosti, pri nekaterih lahko tudi prej. Najbolj opazni in težki simptomi so 
tresavica, bradikinezija (počasno gibanje), togost in nestabilnost pacienta. Za PB 
znanost in medicina še nista odkrili zdravila, so pa na voljo terapije, ki pomagajo 
omiliti simptome, kot sta dopaminska terapija in globinska možganska stimulacija. 
Najbolj pogosta terapija med PB pacienti je dopaminska terapija, vendar ima tudi 
neprijetne stranske učinke, kot je disleksija: resnost stranskega učinka je odvisna od 
velikosti odmerka zdravila. Številne raziskave se ukvarjajo s problematiko disleksije, 
toda zelo malo se jih usmerja v osebnostni pristop k terapiji za PB.  
Ta raziskava je usmerjena v osebnostni pristop zdravljenja PB s pomočjo 
mobilnih in brezžičnih naprav za ocenitev resnosti simptomov PB ter primernega 
odmerka zdravila za pacienta s PB preko pritiska na ekran pametnega telefona. 
Aplicirani pritisk je preveden v analogni električni signal in nato v niz digitalnih 
podatkov, ki so s pomočjo CPLD-ja (Complex Programming Logic Device) poslani 
do pametnega telefona. Z aplikacijo, vključeno na androidnem operacijskem sistemu, 
so digitalni podatki obdelani preko različnih matematičnih funkcij: FFT (Fast 
Fourier Transformations), reakcijski čas in čas premikanja ter s prenosno funkcijo 
tretjega reda za izračun priporočljive količine zdravila. Raziskava obravnava tudi 
problematiko ustvarjanja novih prenosnih naprav, ki bi s svojo prisotnostjo na trgu 
prispevale k boljšemu zdravju prebivalstva, ter njihove prednosti in slabosti.  
 
 
Ključne besede: Parkinsonova bolezen, FFT, CPLD, android, analogna 
tehnika, digitalna tehnika, arhitektura programske opreme 
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Abstract 
Parkinson's disease (PD) is neurodegenerative disorder, which usually 
occurs after the age of 60 and in some cases even earlier. One of the most notable 
and severe symptoms are tremor, bradykinesia (slow-movement), rigidity and 
postural instability.  Medical sciences haven’t found a cure for the PD, however 
there are treatments like Dopamine treatment and Deep Brain Stimulation, which 
may alleviate the symptoms. The most frequently used Dopamine treatment, may 
have severe side effect, such as Dyskinesia, which brings new barrier into PD 
patients’ lives: the severity of Dyskinesia is related to the level of drug 
administration to PD patients.   
Various approaches to addressing Dyskinesia do exist, but none of them 
administers PD drugs according to individual patient needs.  This research proposes 
the use of mobile and wireless hardware and software technologies for estimating 
the severity of PD symptoms, and administering PD drugs according to the 
measurements of PD patient’s pressures of his/her finger on the screen of a mobile 
device.  This pressure, translated into analogue voltage, and digital bits, with the 
help of CPLD (Complex Programming Logic Device) is sent to a smart phone and 
taken by an App in the Android environment.  The computations performed by the 
App will through FFT (Fast Fourier Transformations), Reaction time and Movement 
time calculate the severity of the PD symptoms and decide on the appropriate 
amount of drug administration for that patient, at the moment when the measurement 
has been taken.  The novelty of the proposal is twofold. It allows a high level of 
personalisation in the PD treatment and uses the latest hardware and software 
technologies to bring new solution in the field of drug administration to PD patients.  
The research also debates the issue of creating new gadgets for pervasive 
xii  AbstractSeznam uporabljenih simbolov 
 
healthcare, which is juxtaposed to the powerful Android operating environments and 
proliferation of smart phones.  They can together challenge our need for developing 
more healthcare gadgets in future. 
 
 
Key words: Parkinson's Disease, FFT,  CPLD, Android, Analog technology, 
Digital technology, Software Architecture  
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1 Razširjeni povzetek  
1.1 Optimizacija terapij pri Parkinsonovi bolezni 
Parkinsonova bolezen (PB) je degenerativna motnja centralnega živčnega 
sistema, ki v večini primerov vpliva na motorične sposobnosti bolnika [1]–[3]. 
Bolezen je kronična in progresivna gibalna motnja, pri kateri se simptomi razvijajo in 
postajajo sčasoma vedno bolj moteči v bolnikovem življenju. Najbolj pogosti 
motorični simptomi PB so tresavica, bradikinezija, togost in izguba ravnotežja ter se 
pojavijo pri 1 % svetovnega prebivalstva, starejšega od 60 let.  
PB je povezana z odmiranjem živčnih celic v možganskem predelu substantia 
nagira (posledica nizkega generiranja dopamina) in prisotnostjo Lewyjevih telesc v 
preostalih nevronih. Lewyjeva telesca so skupina proteinov [4], ki se razvijajo 
znotraj živčnih celic in se pojavijo kot sferične mase, ki izpodrinejo ostale 
komponente živčnih celic. Dopamin je kemična spojina, ki pošilja sporočila do dela 
možganov, ki je zadolžen za koordinacijo gibanja. Ko se generiranje dopamina spusti 
pod 80 %, zdravniki že govorijo o začetkih [5] PB in zmanjševanje količine 
generiranega dopamina se zatem ne ustavi. 
 
1.1.1 Simptomi PB 
Vsak pacient s PB bo izkusil bolezen na drugačen način. Nekateri pacienti 
bodo izkusili tresavico, drugi bodo imeli težave zaradi izgube ravnotežja. Razvoj 
bolezni in njenih simptomov je pri nekaterih hitrejši kot pri drugih. PB pacienti imajo 
primarne (motorične) in sekundarne (nemotorične) simptome. Zelo pomembno je 
prepoznati nemotorične simptome, saj lahko v tem primeru začnemo z zgodnjim 
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zdravljenjem bolezni. Nemotorični simptomi se namreč pokažejo v zgodnjih fazah 
bolezni. 
 
Slika 1: PB simptomi in njihove lokacije [6] 
1.1.1.1 Nemotorični simptomi 
Pogosti nemotorični simptomi so: izguba vonja, zaprtost, REM (Rapid Eye 
Movement), težave s spancem, govorom, depresijo, problemi z vidom in zobmi, 
izguba ali pridobitev teže, kožne težave [7]. Glede na lastnosti simptomov 
nemotorične narave lahko zdravniki predvidevajo, kateri od motoričnih simptomov 
se bo pojavil pri pacientu, in glede na te podatke prilagodijo terapijo zdravljenja PB 
vsakemu pacientu posebej.  
1.1.1.2 Motorični simptomi 
Ko PB napreduje, se začnejo kazati motorični simptomi. PB ne moremo 
diagnosticirati z različnimi krvnimi analizami, lahko pa jo zaznamo na podlagi 
pacientove zdravstvene zgodovine in fizičnega pregleda. Glavni motorični simptomi 
so: 
- tremor: v zgodnji fazi PB pacienti izkusijo tresavico kot rahlo tresenje ene od 
okončin (roke ali noge), vendar se lahko pojavi tudi na drugih delih telesa, 
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kot sta čeljust in obraz. Tresavica se pojavi, ko okončina miruje v naročju ali 
prosto visi; roka oziroma noga oscilira s frekvenco 3 – 8 Hz [8]; 
- bradikinezija ali počasno gibanje: pacienti, ki kot simptom PB izkusijo 
bradikinezijo, imajo težave pri opravljanju finih nalog. To pomeni, da pacient 
izgubi spontane gibe in ima probleme z izražanjem obraznih mimik. Najbolj 
pogosti znaki bradikinezije so ponavljajoči se gibi, kot sta tapkanje in togost 
prstov. Pacienti z bradikinezijo imajo težave z vsakdanjimi opravili, kot so 
zapenjanje gumbov, prehranjevanje, hoja, govor itd. [9];   
- togost oziroma nefleksibilnost okončine in vratu: mišice prizadetega uda niso 
sproščene in ne dopuščajo hitrih natančnih gibov. PB pacienti dostikrat čutijo 
otrdelost vratu, ramen ali nog. Togost je neprijetna izkušnja za PB paciente in 
marsikdaj povzroča tudi bolečine v prizadetem udu [10]; 
- problemi z ravnotežjem: to je četrti znak PB. Simptomi se kažejo kot 
nestabilnost in nenadna izguba ravnotežja, ki vodita do pacientovih padcev. Z 
napredovanjem bolezni so simptomi vedno bolj neprijetni in pacient tudi 
dokaj kmalu izgubi neodvisnost [3].  
1.1.2 Trenutni terapiji  
Kot je omenjeno v prejšnjem poglavju, znanstveniki in zdravniki ne vedo 
vzroka za začetek razvoja PB, toda poznajo poti oziroma terapiji za lajšanje 
simptomov PB. Trenutni terapiji sta: 
- dopaminska terapija: v zgodnji fazi bolezni se zdravniki odločijo zanjo [11], 
da z zdravili nadomestijo manjkajoči dopamin. Najbolj pogosto zdravilo, 
katerega predpišejo, je Levodopa in njena mešanica z drugimi substancami. 
Vsakemu PB pacientu se glede na trenutne simptome PB posebej predpiše 
odmerek zdravila, ki olajša trenutne simptome. Kot vsako zdravilo ima tudi to 
svoje neželene učinke, med katerimi so: diskinezija, bruhanje, vrtoglavica. 
Veliko pacientov izkusi vrtoglavico in bruhanje v prve pol ure po zaužitju 
zdravila; ti simptomi določajo največji odmerek zaužitega zdravila v 
posameznem dnevu [12]. Že prej smo omenili, da terapija z Levodopo sproži 
nove in dokaj hude neželene učinke, ki v pacientovo življenje prinesejo nove 
ovire, kot je diskinezija [13]. Tveganje za diskinezijo je odvisno od faktorjev, 
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kot so: starost in začetek PB, razvoj in resnost PB, prepisani odmerek 
zdravila Levodopa ter trajanje terapije [14]; 
- DBS: ta terapija se uporabi, ko postanejo stranski učinki dopaminske terapije 
bolj moteči kot sami simptomi PB in ko zdravilo nima več nobenega učinka 
[15] na simptome. Zdravniki vstavijo v pacientove možgane elektrode, ki 
stimulirajo generiranje novega dopamina: generirajo električne impulze, 
katerim je moč spreminjati amplitudo, frekvenco in trajanje aktivnosti [16].  
1.1.3 Problemi pri optimizaciji PB terapije 
Optimizacija PB terapije nastopi, ko pacient prejme pravilen odmerek zdravila. 
To pomeni, da administrirano zdravilo zatre vse simptome bolezni, izboljša 
vsakdanje življenje pacienta in ne generira stranskih učinkov, ki bi ga ovirali pri 
vsakodnevnih opravilih. Ker zdravniki nimajo dovolj podatkov o pacientovih 
dnevnih aktivnostih in resnosti simptomov, ne morejo predpisati pravilnih odmerkov 
zdravila. Zaradi tega se pacientom predpišejo enaki odmerki zdravil ne glede na 
njihovo aktivnost. Tak način zatiranja simptomov PB hitreje sproži stranske učinke 
terapije in sama terapija postane hitreje neučinkovita. Ne glede na resnost simptomov 
PB ali aktivnost pacienta skozi dan se zaužita količina zdravila ne spremeni. 
Vzemimo primer pacienta s PB, ki opravlja poklic natakarja. Če želi pacient opraviti 
svoje delo, mora simptome zatreti z zdravili v tolikšni meri, da ga ne bodo ovirali pri 
delu. Ko pa pacient pride domov in več ne opravlja nalog, ki zahtevajo natančnejše 
gibe (npr. ležanje na fotelju), ne potrebuje enake količine zdravila kot v službi. Iz 
tega predvidevamo, da bi morali vsakemu pacientu prilagoditi dopaminsko terapijo 
glede na njegove aktivnosti in resnost simptomov.  
1.1.4 Doziranje zdravila za paciente s PB 
Mnogo študij in raziskav je bilo narejenih na področju podaljšanja dopaminske 
terapije in zmanjševanja neželenih učinkov zdravila Levodopa. Glede na dosedanje 
raziskave so znanstveniki ugotovili, da sta stopnja dopamina v krvi in resnost 
simptomov PB v linearni negativni korelaciji, kar pomeni, da manjša kot je količina 
dopamina v krvi, bolj izraziti so simptomi PB. Z željo po obvladovanju simptomov 
PB in povečanju stopnje dopamina v krvi s pravilnim odmerkom zdravila, ki s 
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stranskimi učinki ne bi škodoval pacientu, so znanstveniki začeli reševati problem z 
dvema pristopoma. Eden je uporaba matematičnih modelov, medtem ko drugi sledi 
simptomom in aktivnostim PB pacienta s pomočjo pacientovega dnevnika.  
- PB terapija na podlagi pacientovega dnevnika [17] je pokazala obetavne 
rezultate. Ta pristop je uporaben, če pacient resnost simptomov dosledno 
zapisuje v dnevnik. Zdravniki lahko s pomočjo podatkov iz pacientovega 
dnevnika [18] določijo primerno dopaminsko terapijo, ali pa prilagodijo 
lastnosti impulzov pri DBS terapiji.  
- Drugi pristop k administraciji zdravila sloni na matematičnih modelih, ki 
predpišejo pravilen odmerek za terapijo. Najpogostejši je Tauberijski pristop [19] 
ali prevajalna funkcija drugega reda [20]. V obeh primerih je odmerek, ki zatre 
simptome, izračunan glede na trenutno prisotno količino zdravila v krvi.  
1.2 Predlog 
Naš predlog je sestavljen iz treh podpredlogov, ki bi kot celota pomagali pri 
osebnostnem pristopu k administraciji zdravila za paciente s PB. Prvi podpredlog je 
ocenitev simptomov PB ter matematični izračuni odmerka zdravila glede na trenutno 
izmerjene simptome PB, kot sta tremor (Fast Fourier Transform – FFT) in 
bradikinezija (odzivni čas uporabnika), drugi podpredlog je izdelava strojne opreme 
za izmero omenjenih simptomov, medtem ko je tretji podpredlog izdelava mobilne 
aplikacije za pametni telefon z operacijskim sistemom Android. Mobilna aplikacija 
zna iz izmerjenih podatkov in z nastavljenimi matematičnimi enačbami izračunati 
primerni odmerek zdravila, ki bo zatrl simptome PB in hkrati ne bo generiral novih 
stranskih učinkov.    
1.2.1 Ocenjevanje simptomov PB in odmerka zdravil  
Ocenjevanje simptomov pri pacientih s PB v zvezi z administracijo zdravila 
poteka na več načinov. V tem podpoglavju bomo predstavili možnosti ocenitve 
resnosti simptomov pri tresavici in bradikineziji. Ker sta omenjena simptoma vidna 
na prstih na roki, bomo stopnjo njune resnosti izmerili s pomočjo sile, aplicirane na 
ekran pametnega telefona.  
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1.2.1.1 Ocenjevanje tremorja 
Stopnja dopamina in frekvenca tresavice sta v negativni korelaciji [21], kar 
pomeni, da se z zniževanjem stopnje dopamina povečuje moč tresavice. Frekvenca 
tresavice je 4 – 8 Hz. Iz pridobljenih meritev, ki trajajo 1 minuto s frekvenco 256 Hz, 
aplikacija na pametnem telefonu izračuna spektralno gostoto moči [22] (enačbe 1, 2, 
3 in 4) za vsako frekvenco v frekvenčnem pasu 4 – 8 Hz [21] in normalizira 
izračunane vrednosti, kar je predstavljeno na sliki 1. 
 
𝐴𝑛 = ∑ 𝑥𝑛 sin(2𝜋𝑛)
𝑀
𝑛=1
 (1) 
 
𝐵𝑛 = −𝑖 ∑ sin(2𝜋𝑛)
𝑀
𝑛=1
 (2) 
 𝑃𝑛
2 = 𝐴𝑛
2 + 𝐵𝑛
2 (3) 
 
𝑃𝑎𝑣𝑟 = ∑ 𝑃𝑛
8
𝑛=3
 (4) 
 
Slika 2: Spektralna gostota moči (PSD) pacienta s tresavico 
1.2.1.2 Ocenitev bradikinezije 
Bradikinezija ali »počasno gibanje« je izmerjena s pomočjo sile, aplicirane na 
ParMes napravo. Ko se pojavi dražljaj, začne naprava meriti pritisk, apliciran na 
ekran pametnega telefona. Iz pridobljenih meritev aplikacija na pametnem telefonu 
izračuna reakcijski čas in čas premikanja [19, 23]. Iz pridobljenih podatkov določi 
najvišjo silo, aplicirano med merjenjem, ter iz nje izračuna naslednji lastnosti:  
- reakcijski čas (enačba 5) je čas, izračunan/izmerjen, ko dražljaj spremeni 
svoje stanje in izmerjena sila doseže 10 % največje aplicirane sile; 
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- čas premikanja (enačba 6) je izračunan/izmerjen kot čas med koncem 
reakcijskega časa in trenutkom, ko izmerjena sila doseže 90 % maksimalne 
aplicirane sile. 
 
 𝑡𝑟 = 𝑘10% ×  𝛥𝑡 (5) 
 𝑡𝑚 = (𝑘90% ×  𝛥𝑡) − 𝑡𝑟 (6) 
 
Slika 3: Reakcijski čas in čas premikanja pacienta z bradikinezijo 
1.2.1.3 Matematični izračuni za doziranje zdravila 
Kot pri številnih drugih zdravilih imajo tudi pri izračunu odmerka zdravila 
Levodopa svojo vlogo matematične enačbe. Za izračun pravilnega odmerka zdravila 
so znanstveniki v farmacevtskih podjetjih razvili prenosno funkcijo, ki najbolje 
opisuje učinkovanje zdravila na pacienta s PB:  
 
 
𝐺(𝑠) =  
𝐾𝑒−𝑠𝑇
(1 + 𝑠𝑇1)(1 + 𝑠𝑇2)
 (8) 
 
V članku [24] so avtorji definirali vrednosti K, T1 in T2 z meritvami 
koncentracije zdravila v krvi. Meritve so bile izvedene v 4 urah po zaužitju odmerka 
zdravila (125 mg Levodope). Iz meritev so ugotovili, da začne odmerek zdravila 
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delovati 10 do 15 minut po zaužitju in uspešno zatira simptome naslednji 2 do 2,5 
ure. Po tem času se začnejo simptomi počasi vračati in 4 ure po zaužitju odmerka 
zdravilo nima več nobenega učinka. Ker zdravilo začne delovati po 10 do 15 
minutah, so znanstveniki vpeljali  še spremenljivko 𝑒−𝑠𝑇. 
 
Glede na dobljene izračune zdravniki predpisujejo odmerke, ki zagotavljajo 
1500 mg zdravila na liter krvi [25]. Ta količina zadostuje, da se pri pacientu s PB 
uspešno zatrejo vsi generirani simptomi. Vsebnost zdravila v krvi in resnost 
simptomov sta v linearni negativni korelaciji [21] (podobno kot pri dopaminu), iz 
česar lahko izračunamo želeni odmerek, ki je enak razliki med potrebno in trenutno 
količino zdravila v krvi. Izračunana razlika določi potrebni odmerek, ki zatre vse 
simptome, toda ne škoduje pacientu s PB, saj ne generira neželenih učinkov.  
»Cost function« ali cenovna funkcija odmerka zdravila je rešitev proti 
zmanjšanju količine zaužitega zdravila, kjer δ predstavlja odmerek zdravila in T čas 
med dvema zaporednima zaužitjema zdravila [25]:  
     
𝐹(∆, 𝑇) = 𝑏 × 𝛿 +
𝐶
𝑇
 (9) 
Za zmanjšanje velikosti cenovne funkcije F moramo zmanjšati δ in povečati T. 
δ je impulz, ki določa razmerje med administriranim zdravilom in stopnjo plazme v 
krvi kot njen odziv na prenosno funkcijo sistema drugega reda s časovno 
zakasnitvijo. Amplituda impulza je predpisani odmerek zdravila. Če nam je znan prvi 
odmerek, kateri parafira sistem, lahko izračunamo amplitudo δ, ki je enaka odmerku 
zdravila, in s temi spremenljivkami dobimo časovni odziv sistema: 
    
 𝑌(𝑡) = 40.89 × 𝛿 × (𝑒−1.67(𝑇−0.24) − 𝑒−18.57(𝑇−0.27) (10) 
 
Toda nas zanima potrebni odmerek zdravila RO v vsakem trenutku dneva. Z 
enačbo (10) smo ugotovili RO in enačba je dobila sledečo obliko:  
     
 
𝛿 =
𝑌(𝑡)
40.89 × (𝑒−1.67(𝑇−0.24) − 𝑒−18.57(𝑇−0.27)
 (11) 
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T je določen kot čas med prejšnjim administriranim odmerkom zdravila in 
trenutno administracijo, kjer je Y(t) potrebna stopnja zdravila v krvi, izračunana 
glede na razmerje med simptomi pacienta s PB in zdravega osebka: 
a. Tresavica: prizadeta okončina oscilira s frekvenco 4 – 8 Hz in za izmero 
stopnje zdravila v krvi smo si pomagali s povprečno spektralno gostoto moči 
(SGM) v frekvenčnem pasu 4 – 8 Hz. Iz razmerja SGM pacienta s PB in 
zdravega osebka lahko izračunamo potrebni odmerek: 
 
𝑌𝑡(𝑡) = 1500
𝑚𝑙
𝐿⁄ ×
𝑎𝑣𝑟𝑃𝑆𝐷𝑃𝐷 𝑝𝑎𝑡𝑖𝑒𝑛𝑡
𝑎𝑣𝑟𝑃𝑆𝐷ℎ𝑒𝑎𝑙𝑡𝑦 𝑝𝑒𝑟𝑠𝑜𝑛
 (12) 
b. Bradikinezija: potrebna stopnja zdravila v krvi pacientov z bradikinezijo je 
izračunana glede na reakcijski čas in čas premikanja. Za ocenitev resnosti 
simptomov in izračun potrebnega odmerka zdravila smo sešteli reakcijski čas 
in čas premikanja (za paciente s PB in zdrave osebke). Iz razmerja 
izračunamo potrebno stopnjo zdravila v krvi na sledeči način: 
 
 
𝑌𝑡(𝑡) = 1500
𝑚𝑙
𝐿⁄ ×
(𝑡𝑟 + 𝑡𝑚)𝑃𝐷 𝑝𝑎𝑡𝑖𝑒𝑛𝑡
(𝑡𝑟 + 𝑡𝑚)ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑝𝑒𝑟𝑠𝑜𝑛
 (13) 
 
1.2.2 Strojna oprema 
Za meritev fizičnih lastnosti pacienta s PB smo izdelali strojno opremo, ki 
spreminja svoje električne lastnosti glede na silo, ki se aplicira nanjo. Napravo smo 
razdelili na dva dela. Prvi del je analogni ter prevede silo, aplicirano na napravo, v 
analogni električni signal in kasneje v niz digitalnih podatkov. Drugi del sestavljajo 
digitalne komponente z nalogama uravnavanja porabe električne energije in izvajanja 
meritev sile, aplicirane na napravo.  
1.2.2.1 Analogni del naprave 
Analogni del sestavljajo analogne komponente: »Force Sensing Resistor«, 
merilni mostič, diferencialni operator in analogna digitalna konverzija. Vsaka 
komponenta ima točno določeno nalogo, ki omogoča pravilne in natančne meritve.  
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Uporovni Senzor Sile (Force Sensing Resistor – FSR) 
Uporovni Senzor Sile (Force Sensing Resistor – FSR) [26] nam s svojimi 
lastnostmi omogoča pretvorbo fizične sile, aplicirane na senzor, v električni signal. 
Sestavljen je iz uporovnih lističev, katerih upornost se spreminja glede na njihovo 
deformacijo. Merilni razpon aplicirane sile je od 20 do 2000 g.  
 
Slika 4: Uporovni senzor sile 
Merilni mostič 
Merilni mostiči (Wheatstone bridge) [27] se uporabljajo pri meritvah 
električnih in neelektričnih veličin ter so sestavljeni iz različnih elementov (uporov, 
kondenzatorjev ipd.). V našem primeru smo merili neelektrično veličino – silo. 
Izhoda mostiča sta bila razbremenjena z napetostnima sledilnikoma, katera sta nam 
omogočila pravilno merjenje naših padcev napetosti preko FSR senzorjev. 
 
Slika 5: Shema merilnega mostiča 
Diferencialni operator – DOF  
Glavna naloga DOF-a je izračun napetostne razlike na njegovih vhodih; 
rezultat te operacije je prikaz napetostne razlike med vhodnima napetostma. V našem 
projektu smo zaradi pomanjkanja negativne napetosti uporabili dva DOF-a. S tem 
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pristopom smo rešili naslednji problem: če bi bila namreč napetost na negativni 
sponki DOF-a večja kot napetost na pozitivni sponki DOF-a, bi na izhodu DOF-a 
dobili 0 V oziroma vrednost GND, kar ne bi bila pravilno izračuna napetostna 
razlika. Za rešitev tega problema smo dizajnirali dva DOF-a, pri katerih smo vhodne 
napetosti zamenjali (DOF (IC2C): Izhod = UA – UB, DOF (IC2C): Izhod = UB – UA). 
Izhodni napetosti DOF-a sta nato vodeni na primerjalnik in stikalo. Stikalo preklaplja 
med izhodnima napetostma DOF-a glede na izhod primerjalnika. 
 
Slika 6: Shema diferencialnega operatorja (DOF) – DOPA (IC2D) spodaj in DOPB 
(IC2C) zgoraj. IC1A je primerjalnik za izdajo ukaza za preklapljanje med izhodoma 
DOPA in DOPB. IC3A je stikalo, ki preklaplja med izhodoma DOPA in DOPB 
Analogno-digitalna pretvorba – ADC 
Analogno-digitalna pretvorba – ADC (IC4) [28] služi za pretvorbo analogne 
vrednosti (v našem primeru napetostne razlike DOF-a, ki ima napetost večjo od 0 V) 
v niz digitalnih bitov. Pretvorbe se izvajajo samo takrat, kadar digitalni del ukaže 
ADC-ju, da potrebuje informacije o trenutni analogni napetosti, kakršna je trenutno 
na vhodu ADC-ja. Napetostna sledilnika IC1D in IC1C zagotavljata konstantni 
napetostni vir za čim bolj konstantno referenčno napetost in napetost ukaznega 
načina. 
12 Razširjeni povzetek 
 
 
Slika 7: Analogno-digitalni pretvornik z napetostnimi sledilniki za konstantno 
referenčno napetost 
1.2.2.2 Digitalni del 
Digitalni del služi naši aplikaciji, ki teče na operacijskem sistemu (OS) 
Android, in ob ukazu izvede potrebno število meritev; ko se meritve ne izvajajo, pa 
celotno napravo izključi iz napajanja, da s svojim delovanjem ne skrajšuje 
življenjske dobe baterije. Za digitalni del smo izkoristili CPLD (Complex 
Programmable Logic Device – tip CPLD-ja: 5M60E64C5N [29]), integrirano vezje, 
na katerem se tudi odvija celotna digitalna logika. Sestavljeno je iz štirih komponent: 
integriranega vezja FTDI, nizke porabe energije (Low Battery Consumption – LBC), 
izvajanja meritev (Measurement execution) in UART komunikacije (UART 
Communication). 
 
FTDI – Future Technology Devices International  
FTDI [30] je integrirano vezje za povezljivost z USB protokolom in podpira 
povezavo z različnimi protokoli (RS232, I2C, SPI, UART itd.). V naši raziskavi smo 
uporabili integrirano vezje FT230X, ki ima funkcijo prevajanja UART protokola v 
USB protokol in obratno. Za izbiro integriranega vezja FT230X smo se odločili, ker 
njegovo delovanje podpira tudi OS Android. Vezje ima poleg zagotavljanja 
komunikacije med aplikacijo na OS Android in CPLD-jem še vlogo napajanja naše 
tiskanine in elektronskih elementov z napetostjo 3,3 V. 
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Nizka poraba energije (Low Battery Consumption – LBC) 
Digitalno vezje LBC skrbi za napajanje našega vezja ter izvajanje meritev. 
Zaradi tokovnih omejitev FTDI vezja (maksimalni tok FTDI vezja je 40 μA) se LBC 
vezje prižiga po korakih. Ob zagonu naprave se sprva naloži CPLD logika, medtem 
ko je ostali del vezja izklopljen iz napajanja preko stikala IC8A (slika 43). Ko je 
logika naložena, se lahko pričnejo izvajati meritve. Ko je posredovan ukaz za 
meritev, se omenjeno stikalo preklopi in začne napajati analogni del. To stikalo je 
preklopljeno do konca meritev. Po zaključku zadnje zahtevane meritve se stikalo 
ponovno vrne v stanje OFF in s tem izklopi napajanje analognega dela, da v času 
pripravljenosti porabimo čim manj energije. Ukaz za začetek meritve pride preko RX 
signala serijskega vodila. Za ukaz čakamo startni bit protokola; ko se pojavi ta bit, se 
začne izvajati meritev, tako da nas vsebina preostalih osmih bitov protokola ne 
zanima. 
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Slika 8: Bločni diagram nizke porabe energije (Low Battery Consumption – LBC) 
 
Izvajanje meritev (Measurement execution) 
Izvajanje meritev poteka znotraj integriranega vezja CPLD, ki preko signalov 
CS, DOUT in DCLOCK komunicira z ADC-jem. Prva meritev se izvede, ko preteče 
10 μs od prejema zahteve po meritvi, čemur sledi 2559 ponovnih meritev sile, 
aplicirane na ekran pametnega telefona. Za izvedbo vseh 2560 meritev je potrebnih 
10 s in v tem času lahko pravilno ocenimo PB simptome. 
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Slika 9: Bločni diagram izvajanja meritev (measurement execution) 
 
UART komunikacija  
UART komunikacija pošlje vse zajete meritve aplikaciji na pametnem telefonu. 
Ko signal »done« preide v aktivno stanje, UART logika to zazna in začne pošiljati 
izvedeno meritev. Ker meritev zajema 16 bitov (UART okvir je sestavljen iz enega 
startnega bita, 8 podatkovnih bitov in stop bita), je posredovana v dveh zaporednih 
okvirjih.  
BOUNDRATE
MODUL
TX MODUL
PODATKOVNO 
STIKALO
clk
done
podatkiADC(15:8)
podatkiADC(7:0)
TXCLK
TXCLK TX
 
Slika 10: Bločni diagram UART komunikacije 
 
1.2.3 Razvijanje aplikacije ParMesApp 
Z namenom pravilnega delovanja naprave ParMes in pravilnega izračuna 
odmerka zdravila za tresavico in bradikinezijo pri pacientih s PB smo razvili okolje 
ParMesApp, ki vodi uporabnika skozi potrebne korake meritve. ParMesApp se 
odvija na OS Android. Ta operacijski sistem smo izbrali zaradi naslednjih razlogov: 
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- v prihodnosti bo OS Android verjetno prevladoval na večini pametnih 
telefonov; 
- razvojno okolje Android Studio [31] je za uporabnika preprosto in v nekaj 
korakih se lahko razvije preprosto aplikacijo za pametni telefon.  
 
Za razvoj aplikacije smo imeli dve zahtevi: 
- izdelati je treba arhitekturo programske opreme (SA), na kateri bo delovalo 
okolje ParMesApp, poleg tega mora SA podpirati vse funkcije za pravilno 
delovanje meritev in izračun odmerka zdravila; 
- komponente programske opreme so definirane preko SA za ParMesApp in 
morajo biti prilagojene za Android Studio. 
 
1.2.3.1 Arhitektura programske opreme za ParMesApp 
Zahteve za razvoj rešitve abstraktnega modela za ParMesApp v formatu 
arhitekture programske opreme so narekovale zasnovo UML diagrama z naslednjima 
lastnostma:  
- zajemanje funkcionalnosti aplikacije ParMesApp v uporabnem modelu; 
- definiranje glavne abstrakcije ParMesApp v obliki objektov (objects), 
razredov (classes), atributov (attributes) in operacij (operations), ki bodo 
primerni za ParMesApp diagram.  
Toda ob začetku načrtovanja UI smo hitro ugotovili potrebe za kakovostno 
funkcionalnost ParMesApp. Na sliki 11 je mogoče videti potek UI aplikacije 
ParMesApp, ki vodi uporabnika skozi meritve.  
V prvem UI sta uporabnikom na voljo dva gumba. Zgornji gumb je 
»TREMOR« in je primeren za merjenje tresavice pri pacientih s PB, medtem ko 
spodnji gumb z imenom »Bradykinesia« meri bradikinezijo. Ko pacient s PB izbere, 
kateri simptom želi izmeriti, ga aplikacija začne voditi skozi meritveni proces. Po 
končani meritvi, z vsemi potrebnimi podatki, ParMesApp aplikacija prikaže podatke, 
kot sta resnost PB simptomov in priporočljivi odmerek zdravila.  
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Slika 11: Potek grafičnih vmesnikov pri ParMesApp 
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1.2.3.2 Sekvenčni diagram UML in arhitektura programske opreme 
ParMesApp 
Sekvenčni diagram UML predstavljata sliki 12 in 13, ki sta abstraktni model 
naše aplikacije ParMesApp. Na obeh sekvenčnih diagramih so vsebovani objekti, ki 
predstavljajo objekte uporabniških vmesnikov (rumeni), računske in kontrolne 
objekte (rdeči in zeleni)  ter podatkovne objekte (modri). 
Na sliki 12 se vidi, da objekt kontrolira aplikacijo ParMesApp, ki pripravi 
program in podatke za meritev  tresavice. Posledično potrebujemo FFT (hitro 
Fourierjevo transformacijo), saj moramo izmerjeni signal prevesti iz časovne domene 
v frekvenčno domeno in opraviti izračune za potrebni odmerek zdravila glede na 
trenutne meritve. Podatki, ki so potrebni za izračun FFT-ja in odmerka: 
- senzorsko generirani podatki z naprave ParMes (SGP – senzorsko generirani 
podatki); 
- stalno dostopni depozitorji, kot so npr. podatkovne baze, ki se nahajajo v 
različnih zdravstvenih ustanovah, ki hranijo podatke pacienta s PB. 
Analogija na sliki 13 je zelo podobna analogiji na sliki 12, pri čemer je razlika 
v računskih operacijah, saj na sliki 12 namesto računske operacije FFT uporabimo 
R&M komponento za ocenitev resnosti simptomov PB.  
Sinteza slik 12 in 13 je podana v formatu MVC za ParMesApp aplikacijo, 
katera je lahko prevedena v rešitev SA za našo aplikacijo. Sekvenčna diagrama 
uporabljata različne tipe objektov: uporabniške vmesnike (UI), računske in krmilne 
objekte ter objekte, ki vsebujejo podatke. Na sliki 14 se vidi transakcija iz MVC v 
SA z naslednjima korakoma:  
 izdelava komponent programske opreme iz razredov (classes) abstraktnega 
modela, rezultat pa so objekti v sekvenčnem diagramu;  
 grupiranje komponent programske opreme v sloje.   
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                    Slika 12: Sekvenčni diagram meritve tresavice 
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Slika 13: Sekvenčni diagram meritve bradikinezije 
1.2.3.3 Namestitev SA komponent za ParMesApp 
Model arhitekture programske opreme za ParMesApp je predstavljen na sliki 
12 in 13, medtem ko njegovo namestitev ponazarja slika 14, kjer je uporabljena 
tehnologija J2E [32], ki je ilustrirana s specifičnimi komponentami. Eden 
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pomembnejših delov namestitve naše rešitve je tisti, kjer bo naša programska koda 
nameščena v J2E tehnologiji. 
Začetni 
Zaslon.JSP
Pripravi Meritve za 
TRESAVICO.Servlet
Pripravi Meritve za 
BRADIKINEZIJO.Servlet
Zaslon za meritev 
TRESAVICE.JSP
Zaslon za Meritev 
BRADIKINEZIJE.
JSPPredstavi 
Razultate 
TRESAVICE.JSP
Predstavi Razultate 
BRADIKINEZIJE
.JPS
FFT
.SessionBeans
Izračun Odmerka za 
TREMOR
.SessionBeans
Izračun Odmerka za 
BRADIKINEZIJO
.SessionBeans
R&M TIME
.SessionBeans
SGD-
TREMOR
SGD-
BRADYKINESIA
PACIENT 
DATA
DATABASE
Pridobi Pacientove 
podatke
.EntityBeans
Pridobi Pacientove 
podatke
.EntityBeans
 
Slika 14: UML diagram 
1.2.3.4 Računske operacije za ParMesApp 
Enačbe, omenjene v poglavju 1.2.1 (Ocenjevanje simptomov PB in odmerka 
zdravil), smo uporabili v naslednjih programskih rutinah: 
- enačbe od 1 do 4 so namenjene ocenitvi resnosti tresavice in so uporabljene v 
rutini FFT, ki je na sliki 14 ilustrirana kot FFT.SessionBeans. 
- Za ocenitev reakcijskega časa in časa premikanja – R&M TIME – se 
uporabljata enačbi 5 in 6. Na sliki 14 sta definirana kot 
R&MTIME.SessionBeans. 
- Enačbe od 11 do 13, pri, so implementirane za izračun pravilnega odmerka 
zdravila, uporabljene pa so v DosageCalculation.SessionBeans tehnologiji. 
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1.3 Zaključek  
V tem raziskovalnem delu smo dokazovali, da je možno narediti aplikacijo za 
pametne telefone in izdelati dodatno napravo ter s to kombinacijo narediti korak v 
smeri osebnostnega pristopa k zdravljenju PB. 
Prispevek našega raziskovalnega dela k znanju in praksi: 
- Zasnovali in izdelali smo napravo ParMes, katere edina naloga je meritev 
resnosti simptomov pri pacientih s PB. 
- ParMes je lahko vezana na kateri koli pametni telefon; njegovo operacijsko 
okolje lahko uporabi za določanje odmerka zdravila med terapijo. Povedano 
drugače, napravi ParMes ni treba izvajati nobenih računskih operacij.  
- Računske operacije/enačbe smo priredili za pravilno administracijo zdravil 
(razdelek 1.2.1). 
- Naredili smo prilagodljiv SA za ParMesApp z lastnostmi kasnejšega 
spreminjanja same arhitekture za namen prilagajanja novim terapijam pri PB 
ter izdelali grafični vmesnik (razdelek 1.3.2). 
- Naša aplikacija ParMesApp izvede računske operacije za priporočljivi 
odmerek zdravila glede na trenutne simptome PB; prikazani rezultati veljajo 
za zadnje opravljene meritve.   
 
1.3.1 Prostor za napredek 
Med raziskovalnim delom, razvijanjem strojne in programske opreme, 
simulacijami in popravki smo naleteli na nekaj težav, ki so pritegnile našo pozornost: 
- Netočne meritve so lahko rezultat spreminjanja temperature (lastnosti 
komponent se lahko spreminjajo zaradi spreminjanja temperature) zaradi 
sevanja anten, ki povzročajo motnje (WiFi, NFC, GMS). 
- Poraba energije ParMes naprave skrajša življenjsko dobo baterije pametnega 
telefona. 
- Velikost ParMes naprave je lahko problematična, ker vsebuje velike 
komponente – problem se lahko reši z izdelavo ASIC-a. 
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- Hitrost predlagane rešitve: med delovanjem ne moremo spreminjati nobenih 
parametrov, zato meritve vedno potekajo enako dolgo. Uporabili smo CPLD 
z majhnim številom mikrocelic, kar nas je omejevalo pri dizajniranju 
digitalne logike za CPLD. 
- Med računanjem resnosti simptomov imamo lahko težave s točnostjo 
izračunov, saj nam utegne vsaka napačno izmerjena meritev prinesti napako 
pri končni oceni resnosti simptomov. 
- Pozicija FSR senzorjev ni optimalna. 
 
 
Slika 15: Priključitev ParMes naprave na pametni telefon z aplikacijo ParMesApp 
 
 23 
2 Introduction 
 
This thesis explores the possibilities of using modern software solutions, 
underpinned with mobile and wireless technologies, in order to address the problems 
of drug administration when treating patients with Parkinson Disease (PD). The 
problem of drug administration for PD patients has been very well known for 
decades.  However, it still remains unresolved due to two distinctive reasons: 
a. personalization of medicine is still in its infancy and treatments of PD 
patients heavily depend on a particular patient and the manifestation of PD as 
individual experiences of each patient and 
b. advances in mobile and wireless technologies, which have rapidly changed 
the way healthcare is delivered today, could have enormous impact on PD 
patents, who are often quipped with smart phones and user friendly Apps. 
These patients expect, and possibly require, a new generation of hardware 
and software equipment in order to address their most problematic issue of 
PD drug administration. 
In this research we would like to address a) and b) above by looking at new 
ways of addressing PD drug administration, which are outside current solutions 
developed in the last few decades.  If we focus solely on the PD drug administration 
problem, then we should find a method of collecting information about an individual 
PD patient regarding his/her health status at any moment.  We can then advise the 
patient on the best possible drug administration for that person, at that moment. 
Therefore, PD drug administration will vary from one moment to another throughout 
the day and would be personalized to the health status of one particular patient.  
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It is expected that the modern solution for PD drug administration would 
consist of the combination of a mobile device, with the possibility of it being 
attached to a smart phone, and App, which can run on smart phones.  This is an 
almost unavoidable solution, if we wish to claim that it offers the latest available 
technology for PD drug administration.  Currently there are no Apps which run on 
smart phones and assist in PD drug administration. 
2.1 The Problem 
Any treatment of PD patients involves the extending the Dopamine treatment 
[13] and reducing Levodopa’s side effects [33].  The problems in relation to 
Dopamine treatment is always connected to the lack of precision in administrating 
PD drugs. If a prescribed dosage is too high, PD patients face variety of side effect.  
If the prescribe dosage is too small, it will not suppress PD symptoms and, in both 
cases, patient's wellbeing does not improve.  However, in order to administer PD 
drugs correctly, for the purpose of extending the Dopamine treatment and reducing 
Levodopa’s side effects, we have to measure, in a particular moment, the rigidity of 
PD muscles and the level of tremor a patient experience exactly at that moment.  
Therefore, if the motivation for this research is to address a) and b) from the above, 
the following should be created: 
(i) A device, which can measure the tremor and rigidity of muscles 
(bradykinesia) in PD patients and 
(ii) An App, which takes these measurements and generates an advice on the 
best possible drug administration for that measurement. 
2.2 Objectives of the Research 
There are 5 distinctive objectives of this research. They have been grouped 
around three major activities.  
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The first activity is to find and analyse the state of the art in PD drug 
administration and investigate if any of the existing solutions may have addressed a) 
and b) from the Introduction.  This is summarised in Objectives 1 and 2 below.  
 
The second activity is to investigate if we can develop a device which can 
measure and deliver important data for making decisions on the correct PD drug 
administration, which is summarised in Objective 3 below.  
 
The third activity would be to create a software solution, as an App, which 
could take the data generated by the device and calculate the best possible PD drug 
administration, which is summarised in Objective 4 below. 
 
However, when trying to achieve these objectives, another aspect of this 
research emerged, which was difficult to predict initially and is summarised as 
Objective 5. The idea of creating a new device and using very well know Android 
operating environments for achieving these research goals, prompted a new debate, 
which focuses on the power of Android’s presence in modern software intensive 
systems.  The power of Android may resolve many problems, which were in the past 
resolved by creating new devices and gadgets.  It has to be seen, if the powerful 
smart phones and numerous Apps which run on them would be able to replace the 
need for generating new gadgets in delivering pervasive healthcare.  This research 
shows that the debate on such issues is urgently needed, because we must push 
forward the discussion about the need to address new developments in both fields: 
 Software, such as App/Android combination and  
 Hardware, such a new gadgets for healthcare versus new smart phones which 
might replace them.   
 
The objectives of this research are itemised as follows. 
1. Analysing of the Healthcare Domain for the treatment of PD patients and 
detecting problems, which have not been addressed or resolved yet. The 
Domain of this research is in Healthcare and Drug Administration and the 
problem to be addressed is the difficulty in determining a personalized drug 
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administration for a particular PD patient. The analysis of this problem 
domain is solely based on reading and the literature review.  
2. Identifying Solutions to the problem in 2.1 above and identifying the 
direction of this research.  This depends on solutions developed in the last 
few decades and information on PD drug administration. Both are solely 
available in the literature and published research.  
3. Creating a device, which could measure the pressure of fingers of a PD 
patient in order to determine the level of tremor and bradykinesia (see section 
2.1. above and (i)).  The device should be able to display the output of the 
measurements and pass it as “values” to a software solution which will then 
manipulate it.   
4.  Developing a software environment where the results of measuring the 
pressure of fingers of a PD patient through the device can be manipulated in 
order to make decision on the best possible PD drug administration for a 
particular patient in a particular moment.  Android operating environments 
should be used and an App created upon a specific software architectural 
(SA) solution, which would work for any patient and at any moment. 
5. Evaluating of the results of the research and debating the future of device 
development and Android presence in mobile and pervasive healthcare. 
2.3 The Approach 
The approaches to address the problems identified in this research are 
dependent on research objectives and the way they could be addressed.  Therefore, in 
order to achieve objectives 1 and 2 (O1 and O2), an extensive reading was carried 
out.  The results of achieving O1 and O2 influenced the way the device was created 
and had impact on the way the software, as an Android App, was designed and 
deployed.    
The exact approach to achieve objectives 3 and 4 (O3 and O4) is itemised 
below: 
1. Modelling, verification, simulation, design and assembly of the device, in 
order to achieve O3. 
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2. Performing FFT (Fast Fourier Transform) for determining the severity of 
tremor, reaction and movement time in order to decide on the severity of 
bradykinesia’s symptoms and calculation of the dosage for drug 
administration (using transfer function of third order with delay). These 
would help to achieve O3. 
3.  Developing Software Architectures (SA) for the software solution (i.e. 
Apps), in order to achieve O4. 
4.  Creating an Integrated Development Environment (IDE) for the application 
(App) deployment, using Android Studio, in order to achieve O4. 
5. Designing an App through its SA, equipped with the technology selection of 
the Apps deployment in the IDE, in order to achieve O4. 
6. Compare the available literature with these research results, in order to 
contribute towards achieving O5. 
2.4 Organization of the Thesis 
This thesis is organized as follows. 
In the next Chapter 3, the treatment of patients with PD has been introduced 
and the main problem, in terms of advising on the best possible drug administration 
for a particular patient, at the moment when the severity of his/her PD symptoms are 
measured, have been identified.  The chapter also gives an extensive related work 
which highlights published research form the same problem domain. Chapter 4 
proposes a novel way of addressing the severity of symptoms of PD patients and the 
way the drugs could have been administered.  A particular mobile device, which is 
able to measure the pressure of PD patient’s fingers on its screen, has been developed 
and attached to a smart mobile phone.  An Android Apps has been designed, and its 
SA given by looking at the App’s deployment on the smart phone. In Chapter 5 the 
implementation has been described and Chapter 6 concludes by giving an evaluation 
of this research and pinpoints towards future works. 
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3 Background and Literature Review  
3.1 The Background: The Optimization of Parkinson’s Disease 
Treatment 
Parkinson's disease (PD) is a degenerative disorder of the central nervous 
system mainly affecting the motor systems [1] [3] [2]. It is a chronic and progressive 
movement disorder, meaning that symptoms continue and get worsen with the time. 
Most common motor sings for PD are tremor, rigidity, bradykinesia and postural 
instability and PD is present at 1% of people over 60 years old. 
PD is connected with death of nerve cells in substantia nigra (as a 
consequence of low production of dopamine) and present of Lewy bodies in 
remaining neurons. Lewy bodies are abnormal aggregates of protein that develop 
inside nerve cells and appear as spherical masses that displace other cell components 
[4].  Dopamine is a chemical that sends a message to the part of the brain for 
coordination and movement. When production of the dopamine drops below 80%, 
physicians are already talking about PD [5] and with the time amount of dopamine 
doesn't stop decreasing.  
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Figure 16: Part of the brain were PD starts develop [34] 
3.1.1 Symptoms of PD  
Each patient will experience the disease in a different way. Some patients will 
have tremors while others may have problems with their balance. The progress of the 
disease will be more aggressive for some than others.  PD patients have primary 
(motor) and secondary (motor or non-motor) symptoms.  It is important to recognize 
non-motor symptoms very early in order to start treatment on time. Non-motor 
symptoms occur in the early stages of PD.   
 
Motor symptoms appear on one side of the body and as time passes, PD starts 
affecting the other side. Usually symptoms are not as severe as on the initial side. 
Transition of symptoms from one to the other side cannot be predicted.  It may take 
from a few months to many years, and if differs from patient to patient.  The most 
common motor symptoms are tremor, bradykinesia, rigidity of macules and postural 
instability.  
 
3.1.1.1 Non-motor Symptoms  
Common non-motor symptoms are: loss of sense of smell, constipation,  
REM (Rapid Eye Movement) sleep behaviour disorder (problem with sleeping), 
mood changes, orthostatic hypotension (low blood pressure when standing up), 
speech, depression, vision and dental problems, weight loss or gain, skin problems 
[7]. When diagnosing non-motor symptoms, which usually occur at early stages of 
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PD, doctors may decide about the treatment for an individual patient separately, 
which in turn would be used to predict the occurrence of motor symptoms.  
 
3.1.1.2 Motor Symptoms 
When PD progress, motor symptoms start appearing. PD can not be diagnosed 
by different blood or autopsy tests.  The disease can be detected through patient 
medical history and physical examination. Main motor symptoms are: 
- Tremor: In the early stages of PD, patients experience a slight tremor in one 
of the limbs such as hands or feet.  It can even appear in the jaw or face but it 
is less common. Tremor usually occurs when a limb, it starts slightly shaking 
or oscillating with frequency 3 ÷ 8 Hz [8]. This behaviour is noticed, for 
example, when hand is resting on the lap or when the arm is hanging loosely 
at the side. However, the tremor stops when a person starts preforming 
different actions with the hand or the foot. Some patients have noticed, if he 
or she shapes his or her hand into the fist or if the hand is in constant 
movement, the tremor stops.  
- Bradykinesia: is a word for “slow movement”. People with Bradykinesia 
have problems with movements which require to perform “fine” tasks. This 
means that a patent losses spontaneous movements (hand gesturing, 
speaking) and has difficulties with facial expressions.  Most common signs 
for Bradykinesia is repetitive movements such as finger taping and stiffness 
of the finger [9]. Daily tasks such as buttoning a shirt, brushing teeth, 
preparing or eating a food and walking are affected.  They need more time to 
preforms these tasks. Their speech becomes quieter and more monotone - 
called hypophonia. 
- Rigidity: causes stiffness and inflexibility of the limbs, neck and trunk. 
Muscles of the affected limb are constantly stiff and do not relax. PD patients 
usually feel tightness in their neck, shoulder or leg. Rigidity can be 
uncomfortable or even painful [10]. 
- Postural Instability: this is a fourth sign of PD which can be present at 
diagnoses. It is manifested as lack of balance associated with increased falls 
and loss of independence.  When the disease progresses, symptoms become 
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more prevalent and they usually worsen. These are the most disabling 
symptoms of PD [3]. 
 
Figure 17: PD symptoms and their location [6] 
 
3.1.2 Cause and Treatment of PD 
Couse for PD is unknown to scientists and physicians [35].  However, they 
have found, that environmental and genetic factor effect the production of dopamine: 
- Genetic factor: Hereditary inheritance is seen in 10% of patients with PD 
[36]. 
- Environment factor: Many studies have been carried out on the impact of 
environment on the development of PD. The usage of pesticides have been 
mentioned and farmers, people who live on rural areas, or people who drink 
well water (contaminated groundwater with pesticides) have more chances of 
developing a PD then the others [37]. Pesticide are not the only toxicants 
which contribute to development of PD.  There are other substances which 
increase the risk for PD, such as metal [38] and air pollution [39].   
 
PD cannot be cured, however doctors can alleviate symptoms with different 
treatments. In very early stages of PD patients can help themselves with changed life 
style: physical exercises, healthy diet, i.e. eating verity of food [40]. Caffeine intake 
and apparently smoking helps to alleviate the PD symptoms, because nicotine has a 
positive reaction on production of dopamine [40]). When PD progresses to high 
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states and symptoms become more severe, the doctors choose more aggressive and 
invasive treatments like Dopamine treatment [14] and Deep Brain Stimulation [41]. 
3.1.2.1 Dopamine Treatment  
At the later early stages of the PD, doctors tend to replace missing dopamine 
with drugs [11]. Most common and widely used drugs is Levodopa and its mixture 
with other substances. Every patient has different dosage of Levodopa which differs 
on state of the severity of symptoms and on wellbeing of the patients. However, 
Levodopa, as any other medicine, has its side effects on patients known as 
Dyskinesia [14], vomiting, dizziness, hallucinations, etc. With progress of PD the 
dosage has to be increased. Drug increment suppresses and hides PD's symptoms.  
However, on the other side, Levodopa’s side effects become more severe and 
disturbing with the increase dosage. One of more disturbing side effect is Dyskinesia 
[5].  It is more common in younger patients and shows as involuntary movements of 
upper body or lower extremities (uncontrolled movement of hands, etc.). When drugs 
become ineffective and Dyskinesia become more severe, doctors choose other 
treatments, which are more invasive, such as Deep Brain Stimulation. 
3.1.2.2 Deep Brain Stimulation 
DBS treatment is administered when the drugs do more harm than good [42].  
When physician change the treatment from Dopamine treatment to DBS, surgeon 
with surgical intervention implements two or more electrodes into subthalamic 
region specifically into subthalamic nucleus or globus pallidus part of the brain, 
based on primary PD symptoms [43]. With electrical pulses, DBS simulates 
production of dopamine and increases its levels. Pulse: amplitude, duty cycle and 
frequency and based on symptoms, and doctors, through the console, can change 
pulse’s properties in order to increase wellbeing of patient and reduce disturbing 
symptoms which patient has [41].  
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Figure 18: Deep Brain Stimulation [44] 
3.1.3 The Problem in the Optimization of PD Treatment  
Optimization of PD treatment occurs when PD patients get the correct dosage 
of drugs. This means, that administrated medicine has to suppress all symptoms, 
improve patient's wellbeing and not generate side effects which will harm the patient. 
Because doctors don't have enough data about patient’s daily activities and state of 
symptoms, they cannot predict the correct dosage of drugs and administer drug 
correctly. Therefore, all patients get the same amount of prescribed drug.    
3.1.3.1 Current Treatments 
As mentioned in the previous section, scientists haven't found the cause, 
which triggers and starts the developing of PD, but they have found a way to 
alleviate the severity of PD symptoms. Currently available treatments are:  
- Dopamine treatment: Widely used drug for dopamine treatment is Levodopa 
which it has its side effect like Dyskinesia, dizziness, hallucinations, nausea, 
vomiting etc. Most patients experience nausea and vomiting in half hour 
window after administration of each medicine in a day and these symptoms 
determent maximum administrated dosage for each patient [12]. We have 
already mentioned that Levodopa treatment develops severe side effects 
which bring a new disability into PD patients’ lives, such as Dyskinesia [13]. 
The risk of Dyskinesia depends on age and the start of the PD, progress and 
severity of PD, dosage of drug and the duration of levodopa treatment [14]. 
- Deep Brain Stimulation: this treatment comes in practice when side effect of 
Levodopa becomes too severe  and medicine hasn't got any effect [15] on 
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improving of patient's wellbeing. Inserted electrodes into the patient's brain 
stimulate the production of dopamine: with electrical signal and their 
amplitude, frequency and duty cycle [16].  
 
It is difficult to interfere with DBS. It appears that there are more options 
in terms of improving PD treatments if we look again at the way we administer 
drugs for each PD patient. Therefore, this research will focus on the on 
administration of drug in dopamine treatments. 
 
We have already mentioned in early stages of PD, doctors prescribe 
Levodopa as a PD treatment, and every patient with PD gets the same prescribe 
dosage of a drug [45]. Furthermore, the administration of drug is same 
throughout all day. This approach of suppressing symptoms develops side effects 
quicker and effect of treatment becomes ineffective [46]. Regardless of PD 
symptom severity or activity of a patient throughout a day, administration of drug 
stays the same [47]. For example, if occupation of a PD patient is a waiter and if 
he wants to do his job well, he or she has to suppress symptoms with drugs at 
work. However, when the PD patient is at home, lying on the couch, he or she 
doesn't need to suppress PD symptoms as hard as he or she has to at work [20]. 
Every patients needs different drug administration during the day, which is based 
on his or her activities and level of his or her symptoms.  
3.1.3.2 Administering Drug for PD Patients  
In order to extend the Dopamine treatment and reduce Levodopa’s side 
effects, many studies have been carried out towards the optimization of dosage of PD 
drug. The amount of dopamine in the blood and PD state have negative correlation 
[21], which means the higher the state of PD, less dopamine is produced. In order to 
decrease PD’s symptoms and increase the level of dopamine with correct amount of 
drug administration, which won't harm patients in any way, scientists tried two 
different approaches. One is with mathematical models for administration of 
medicine [48] and the other is with the tracking progress of PD through the patient’s 
diary. 
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- PD treatments based on patient’s diaries [17] showed promising results. This 
helps if a patient keeps his or her diary up to date. Doctors with diary's data 
may set up appropriate drug administration or change settings of DBS. This 
approach was described in [43] and proved that wellbeing and length of 
sleeping of the patient has been improved. The wellbeing (they were using 
“feeling” score) of the patient dropped when medicine dosage was increased, 
because wellbeing dropped with the appearance of Dyskinesia. Doctors may 
change the treatment (decrease drug dosage and change settings of DBS) and 
wellbeing returned. In order to achieve constant patient’s wellbeing, doctors 
have to track diary's data [18] and prescribe treatments which will not bring 
new disabilities into PD patient's life. 
- Second mode for administering medicine are based on mathematical models 
for predicting correct treatment. The most common is Tauberan approach 
[19] or transfer function of second order [20].  In both cases, amount of 
required administrated medicine for suppressing symptoms of PD are 
determining by the concentration of the drug in blood and the time of 
administration.   
3.1.4 The Problem to Be Addressed: The Drug Administration 
This research will be focus on the problem of Dopamine treatment, amount of 
administrated PD drug. If the prescribed dosage of the drug is too high PD patient 
has a variety of side effect [33].  If the prescribe dosage is too low, the drug will not 
suppress symptoms and in both cases patient's wellbeing does not improve. The 
approaches described in section 3.1.3.2 have their drawbacks: 
- When treatment was based on a PD patient’s diary, doctors faced numerous 
problems in terms of incomplete and constantly missing data [49].  
- When treatments or drug administration were based on mathematical models, 
doctors are able to decide upon it by measuring severity parameters and 
calculating the correct amount of drug administration [50]. However, these 
measured parameters vary from patient to patient and in this approach the 
specificity of PD symptoms are lost for an individual patient: all patients get 
the same dosage of medication.  
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Currently, there are no solutions which can improve current approaches to the 
treatment of PD.  None of them can predict the exact dosage for a PD patient and if 
they are able to approach it, the personalisation of PD treatment has been lost.   
 
From this perspective, new solutions are needed in order to determine the 
specificity and severity of PD symptoms in each individual patient, and at different 
moments throughout each day of their lives. This would be the most effective 
administration of PD drugs, which will have good impact on PD patients wellbeing. 
3.2 Related Work  
The research of this project belongs to e-Health domain. There are numerous 
projects across the world which address the problems in remote monitoring of 
patients [51], in order to increase patients wellbeing and make their lives independent 
from others. EU founds various project which are focused on remote monitoring and 
increasing wellbeing of the patients during any treatments. The domain which covers 
this area is called e-Health and it combines electronic information and 
communication technology in the healthcare environment [52]. In [52] which gives a 
survey on EU project in e-Health and telemonitoring we find projects on: Comfort 
and security telemonitoring, Rehabilitation telemonitoring, Chronic diseases 
telemonitoring. In Comfort and security telemonitoring they covered projects which 
are not dedicated to disease treatments however, researchers covered projects which 
help elderly people with their wellbeing. Studied projects use different platforms for 
their application like TV, mobile phones and smart houses. In Rehabilitation 
telemonitoring, they combine project which monitors patient's performance and 
virtual rehabilitation. In Chronic diseases telemonitoring there are projects which 
monitors patients in homecare and analyse the security, impact of cognitive science 
on and the existence of universal e-Health systems. In the last decade, mobile and 
wireless technology market is rapidly expanding on various every day activities and 
wellbeing and it has positive impact [53][54] on our everyday lives, health and 
economic status [55]. In the last few years, we have witnessed rapid proliferation of 
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different wearable activity [56] and medicine devices [56] (clothes, belts or watches 
with integrated sensors for measuring variety of physical properties from blood 
pressure, heart beat, number of steps (pedometer), etc.) which have been paving the 
way towards pervasive and personal healthcare. 
 
PD is a disease which rapidly spread spreads between global population and 
effects patients as a motor disability [1] and it has been attracted attention of various 
research which dedicated their time in telemonitoring and e-Health. In this domain 
we can find a variety of researches and papers with focusing on optimization of the 
treatment and alleviating of the PD symptoms with Tauberan [19] mathematical 
model where based on symptoms and time of previous drug administration they 
calculate correct amount of drug to suppress the symptoms and different techniques 
for diagnosing and monitoring PD patients [43] through diaries, filled up by patients 
or sensor generated data. Different teams develop application for accurate 
telemonitoring and managing symptoms through speech test [57]. Trying to find the 
cause of PD, doctors and scientists exploited wireless body area networks which 
show activities and behaviour of PD patients [58] during a day and for understanding 
nero generative disease and managing of them. 
 
In terms of addressing the optimisation of PD treatment, there are various 
approaches which range from very well know Tauberian approach [19], where 
mathematical models determine the amount of drug administration as well as time of 
their administration. A support tool for optimal levodopa administration [43], uses 
patients diaries for optimizing deep brain stimulation with combination of anti-
Parkinson’s drugs. Diary shows the effects of the treatment on wellbeing of PD 
patients and with the collected data, doctors can set up correct parameters for Deep 
Brain Stimulations without side effects caused by drugs like Dyskinesia [14], [59]. 
 
The papers which come slightly closer to our area of interest study tremor 
frequency [21], measure patient’s response time – “slow movement” or bradykinesia 
[60], and develop quantitative methods for measuring these PD symptoms. Scientists 
have taken two different approaches for measuring or detecting PD symptoms with 
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help of contact and contact less devices. Contactless devices make the use of motions 
cameras called kinetic [61], where camera’s software can extract motions of the 
user’s floating hand seen by camera and based on hand gestures in 3 dimensional 
space, determines severity of disease. Second approach is contact device where 
user/patient has to be in contact with the device to measure current state of the 
disease. To evaluate the severity of symptoms different sensors are taking place in 
this case like touching sensors (with resistive or capacitive properties) or gyroscopes 
or accelerometer and they can be as wearable sensors or standalone sensors [62] [41] 
[63]. These sensors are allowing to measure finger tapping and extracting frequency 
for quantitative diagnosis of PD, measure maximum pinching force to evaluate 
bradykinesia [23] and using combination of all contact sensors to evaluate tremor 
[42], bradykinesia, righty and postural instability as well as drug’s side effects like 
Dyskinesia [63]. When we were making a research and looking for applications in 
rehabilitation with connection of wearable sensors [63], we have found different 
wearable sensors applications which use motion analysis lateral belt worn 
accelerometer [42]. 
 
The field of smartphones and their applications for PD patients, which will 
help PD patients to improve their daily wellbeing,  has been very poorly researched 
duo to the lack of integrated sensors into smartphones [64]. There are publications 
which monitors wellbeing though Apps using non-invasive way such as tapping on 
the screen [65]. However, there is no peer reviewed papers which focus solely on 
PD. The only publication which promotes a smart phone application for the detection 
of tremor is available at [65]. 
 
 
 
 
 
 
 
 
The Proposal – Device and Software App for PD Drug Administration 39 
 
 
4 The Proposal – Device and Software App for PD Drug 
Administration 
This chapter introduces our proposal, which consists of two parts: (1) ParMes 
device which will be used for measuring the severity of PD symptoms (section 4.2) 
and (2) ParMesApps Android App which will take these measurements and calculate 
the best possible drug administration for a PD patient at the time when the 
measurement was carried out (section 4.3). However, before we introduce the 
proposal, we offer a more detailed explanation in section 4.1. on how the severity of 
PD symptoms can be estimated through ParMes. 
4.1 Estimating Symptoms of PD and Drug Administration 
 
This section shows how the severity of the tremor and bradykinesia can be 
estimated. It is based on measuring of the applied force on the screen of a smart 
phone. Therefore, ParMes device will be suited only for PD patients with tremor and 
bradykinesia, because these two symptoms are manly visible on hands and can be 
measured through hand's gesture. 
4.1.1 Estimating Tremor  
Level of dopamine and tremor's frequency are in negative correlation [21], 
which means, when patient has low dopamine level, the power of tremor will be 
higher.  Tremor's frequency occurs between 4 ÷ 8 Hz [21]. From obtained measures, 
which were taken for time period T and with sample frequency 256 Hz, application 
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will calculate the Power Spectrum Density (PSD) [22] for every frequency in band 
pass between 4 ÷ 8 Hz and then normalized the values, which is illustrated in Figure 
19.  
  
 
𝐴𝑛 = ∑ 𝑥𝑛 sin(2𝜋𝑛)
𝑀
𝑛=1
 (14) 
 
𝐵𝑛 = −𝑖 ∑ sin(2𝜋𝑛)
𝑀
𝑛=1
 (15) 
 𝑃𝑛
2 = 𝐴𝑛
2 + 𝐵𝑛
2 (16) 
 
𝑃𝑎𝑣𝑟 = ∑ 𝑃𝑛
8
𝑛=3
 (17) 
 
Figure 19: Power Spectrum Density (PSD) of patient with tremor symptoms 
4.1.2 Estimating Bradykinesia 
Bradykinesia or “slow movement” is measured with help of applied pressure 
on the ParMes. When stimulus appears, device will start tracking and measuring 
pressure which is applied on the screen. From obtained measurement data, 
application will extract reaction time and movement time [23] [20]. It also has to find 
a highest value of applied pressure and based on this value it calculates following 
values as shown in Figure 20: 
-  Reaction time (Eq. 18) is measured as the time when stimulus changes its 
state and measured signal will reach threshold point which is 10% of the 
measured sample with the highest value. 
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-  Movement time (Eq. 19) is measured as the time between the end of reaction 
time and when signal passes threshold 90% of the measured sample with 
highest value. 
 𝑡𝑟 = 𝑘10% ×  𝛥𝑡 (18) 
 𝑡𝑚 = (𝑘90% ×  𝛥𝑡) − 𝑡𝑟 (19) 
 
Figure 20: Response and Movement time of patient with Bradykinesia 
4.1.3 Drug Administration Calculation 
Even mathematics has taken place in the optimization of Levodopa treatment. 
In pharmaceutical industry, producers of Levodopa medicine, developed transfer 
function of the second order with drug administration as input. The output is 
medicine concentration in blood, as given by [20]: 
 
𝐺(𝑠) =  
𝐾
(1 + 𝑠𝑇1)(1 + 𝑠𝑇2)
 
(20) 
 
In this article, the authors determined K, T1, T2 values by measuring 
medicine concentration in blood, several times after the patient with PD 
administrated was 125mg of Levodopa. These measurements were repeated 4 hours 
after the administration of the drug and they noticed that drug starts working after 10 
÷ 15 min after the drug administration. When effect of drugs reaches optimization 
level, the symptom stays suppressed for 2 ÷ 2.5 hours and from that time forward, 
the effect of drugs start fading out. After 4 hours effect of drugs disappears.  Because 
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medicine has 10 ÷ 15 minutes delay after administration, authors of the paper [20]  
added another variable in order to transfer function of the second order 𝑒−𝑠𝑡 where t 
is delay time. And now equation gets following form[24]: 
 
 
𝐺(𝑠) =  
𝐾𝑒−𝑠𝑇
(1 + 𝑠𝑇1)(1 + 𝑠𝑇2)
 
(21) 
 
The equation models pharmacodynamics of the drug and describes the 
relation of administrated drug and effect of the drug, i.e. its amount in blood. Doctors 
predicts that 1500mg/L [25] of the medicine in blood is enough to suppress the PD 
symptoms. The level of and severity of the symptoms are in negative linear 
coloration [21] and from that, we can calculate the difference between the current 
amount and desired amount of medicine in blood. With this difference we can 
determine required dosage of medicine, which won't harm wellbeing of the patients 
and will suppress symptoms. 
 
Cost function of medicine usage is solution for reducing amount of 
administrated medicine, where 𝛿  presents dosage of the medicine and T time 
between two séances of drug administration’s [25]:  
 
 
𝐹(∆, 𝑇) = 𝑏 × 𝛿 +
𝐶
𝑇
 
(22) 
 
In order to reduce cost function F, we have to decrease 𝛿 or increase T. 𝛿 is 
an impulse which determents relation between medicine administration and plasma 
level in blood and it is a response of a transfer function second-order system with 
time leg. Amplitude of the impulse is amount of prescribed medicine. If we know 
first applied dosage, which initialled the system, amplitude of impulse 𝛿 is the 
amount of the second dosage, the time response of the system will be:  
 
 𝑌(𝑡) = 40.89 × 𝛿 × (𝑒−1.67(𝑇−0.24) − 𝑒−18.57(𝑇−0.27) (23) 
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However, we are interested in the amount of prescribe 𝛿 at any time in a day. 
From equation (Eq. 23) we excreted 𝛿. And final equation for administration of 
drugs is gets following form; 
 
 
𝛿 =
𝑌(𝑡)
40.89 × (𝑒−1.67(𝑇−0.24) − 𝑒−18.57(𝑇−0.27)
 
(24) 
 
T is determent as time between previse administration and current 
administration. Where Y(t) is desired level of drug in blood, and it is calculated 
based on ratio of symptom’s severity at patient with PD and health person in same 
measurement range: 
a. Tremor: The affected limb oscillates with frequency between 4 ÷ 8 Hz and to 
calculate desired level of drug in blood, we estimate severity of tremor on 
average PSD (Eq. 17) in bandpass from 4 ÷ 8 Hz. Ratio is calculated from 
average PSD of PD patient and healthy person and from ratio we can 
calculate desired level of drug in blood on following way:  
 
 
𝑌𝑡(𝑡) = 1500
𝑚𝑙
𝐿⁄ ×
𝑎𝑣𝑟𝑃𝑆𝐷𝑃𝐷 𝑝𝑎𝑡𝑖𝑒𝑛𝑡
𝑎𝑣𝑟𝑃𝑆𝐷ℎ𝑒𝑎𝑙𝑡𝑦 𝑝𝑒𝑟𝑠𝑜𝑛
 
(25) 
 
b. Bradykinesia: Desired level of drug in blood for patients with Bradykinesia is 
calculated based on reaction and movement time. To evaluate correct amount 
of drug, we summed reaction (Eq. 18) and movement (Eq. 19) time of PD 
patient and healthy person. Based on summation and ratio between 
summation, we calculated desired level of drug in blood on following way: 
 
 
𝑌𝑡(𝑡) = 1500
𝑚𝑙
𝐿⁄ ×
(𝑡𝑟 + 𝑡𝑚)𝑃𝐷 𝑝𝑎𝑡𝑖𝑒𝑛𝑡
(𝑡𝑟 + 𝑡𝑚)ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑝𝑒𝑟𝑠𝑜𝑛
 (26) 
4.2 Developing ParMes for Measuring Finger Pressure 
The main purpose of ParMes is to measure applied pressure of a human 
finger on its screen.  It is important to note that we have two options.  We can either 
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 attach ParMes on the back of a smart phone, in which case ParMes becomes a 
”slave” or  
 create a completely new device which would not need a smart phone and 
would perform all: measurements, their calculation and interaction with a PD 
patient.  
 
In case that we chose option 1, we will be able to use parts and functionalities 
of smart phones and take advantage of numerous software solutions, which exist on 
smart phones, in order to deliver services expected by a PD patient.   
 
In case we choose option 2 we would need more time and resources in order 
to deliver both: create hardware parts for ParMes (including screens) and design 
software which does not necessary offer as attractive operating environments as our 
smart phones do.  
 
Obviously, option 1 appeared to be the only way forward in this research and 
our choice will be evaluated in a separate section.   Consequently, “the screen”, 
which we refer to in this research, is a screen of a smart phone and therefore ParMes 
should behave as a slave device. When ParMes receives a request to measure a 
pressure caused by a PD patient’s finger, it starts measuring applied force on the 
screen and sends the results of the measuring to a master device, which is always a 
smart phone.  Therefore, smart phones are here to manipulate the measurements of a 
pressure caused by a human finger.  ParMes is attached to a smart phone and, in 
order to save power in its battery, ParMes is consuming power only when 
measurement is required. 
 
There are two important issue to be addressed before ParMes was designed.  
Firstly, the time between the beginning and the end of the measurement of a pressure 
caused by a human finger with ParMes is 10 seconds, in which ParMes sends 256 
samples of applied force per second.  Secondly, we will have to design hardware 
which will meet special requirements: it has to be small enough, that it will be 
convenient to use. ParMes includes some basic analogue components such as 
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operational amplifier, switches and elements with resistive and capacitive properties 
and digital logical operators such as AND, OR, NOR, NAND, XOR, MUX and D-
FlipFlops. They are essential for creating hardware parts of ParMes.  They will 
naturally convert into electrical circuits which would constitute the analogue and 
digital parts of ParMes.   
 
Therefore, ParMes is constructed from two main parts: 
 Analogue part which measures voltage resulting after applying finger 
pressure and  
 Digital part which transforms these measurements into digital streams 
and manages ParMes.  
 
However, the design of ParMes‘s hardware does require 
(i) the environment with tools where we could perform the construction of 
electrical circuits and  
(ii) adequate diagrams which would illustrate the design. 
 
For (i) Altium Designer has been used and Altera Quartus II and Altium 
Designer serve for (ii). We will use Altium Designer for modelling of the circuit and 
for its construction, while Altera Quartus will be used for constructing digital parts. 
Visio 2010 is used for (ii) in order to illustrate digital parts of ParMes. It is important 
to note that the design of Software Application, which uses data generated by 
ParMes is covered in a separate section.  It will require a completely different design 
environment in order to model software architectural solutions for the generation of 
software application, which will in turn deliver services to PD patients based on 
ParMes. 
 
Figure 21: PCB Hardware Design of ParMes 
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4.2.1 Analog Part of the ParMes 
Analogue part of ParMes translates applied force on the screen into a stream 
of bits, with help of the components described in 4.2.1.1. – 4.2.1.5. 
4.2.1.1 Preparing Environment for Hardware Design: Altium Designer  
Altium Designer [66] is an electronic design automation software package 
Figure 22. for printed circuit board, FPGA (Field – Programing Gate Array) and 
embedded software design. In this project, it was used for developing printed circuit 
board. It also supports importing new component libraries and schematic capture and 
3D PCB (Printed Circuit Board) design. This program was used for design of model 
circuit is in Appendix Error! Reference source not found. and Error! Reference 
source not found. and PCB place and route of ParMes is in Appendix Error! 
Reference source not found.. 
 
Figure 22: Altium Designer - Left figure presents development environment for 
modelling the circuit while right figure presents place and route of the circuit based 
on model of the circuit 
4.2.1.2 Force Sensing Resistor – FSR 
Force resistive sensor (FSR) is pictured in Figure 23.  It translates applied 
pressure of a PD patient’s finger into resistance of FSR [26]. Therefore, resistance 
and pressure are in negative linear correlation, which means when an applied force of 
a finger increases, the resistance of sensor is decreased and the other way around. 
FSR can measure pressure from 20g to 2000g [26] and it is designed for applications 
where small changes in pressure are expected. To measure a pressure accurately, 
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ParMes has four FSR sensors at every corner of the smart phone, between the rear 
side of the smart phone and solid base on which FSR sensors are attached.   
 
Figure 23: Force Sensing Resistor (FSR) [26] 
4.2.1.3 Wheatstone Bridge 
Wheatstone bridge [27] is illustrated in Figure 24: Wheatstone Bridge. It 
shows the measuring of small resistance changes in FSRs. The output voltage from 
WS is the difference between voltage ratios of 
𝑃3+𝑅17
(𝑃3+𝑅17)+(𝑃1+𝑅14)
× 3𝑉3_𝑆 and 
𝑃4+𝑅18
(𝑃4+𝑅18)+(𝑃2+𝑅15)
× 3𝑉3_𝑆 [27]. In other words, voltage difference between point 
UA and UB in Figure 24. Therefore, every ratio branch is treated as separated 
voltage divider.  Divided voltage is filtered with low pass RC filter with cut-off 
frequency 48Hz. Cut-off frequency is in relation with PD described in upper parts of 
the research and it is designed to cut-off all undesired noise. There are two RC filters 
on Figure 24: first RC filter consists resistor R20 and capacitator C15 and second RC 
filter resistor R21 and capacitator C16 and both outputs of filters are relieved with 
voltage followers. Voltage follower (Figure 24, IC2A or IC2B) is component where 
output voltage follows the input voltage and relieves voltage divider. In IC2A case 
output 1 follows input 3 while input 2 is connected as a loopback in order that output 
follows input 3. The same happens with IC2B where output is 7 and inputs are 5 and 
6. Outputs of the voltage followers (UA and UB) are outputs voltage of Wheatstone 
bridge. In Figure 24 FSR are marked as P1, P2, P3 and P4. 
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Figure 24: Wheatstone Bridge 
 
4.2.1.4 Differential Operator – DOP  
Differential operator (DOP) is shown in Figure 25.  Its task is to find a voltage 
difference between outputs UA and UB of Wheatstone bridge. There are two DOP, 
because of the lack of negative supply voltage in the circuit. For example, if we are 
subtracting UA – UB and UB is grater then UA, we will respectively receive 
negative voltage on its output. In this case we will receive 0 on output of DOP 
because the lowest voltage is 0V and DOP can’t go under this voltage. To bypass this 
problem we use two DOP, where DOPA subtracts UA-UB and DOPB subtracts UB-
UA. Output of DOFs (DOPA and DOPB) are then fed into a comparator and a 
switcher. Comparator compares DOPA and DOPB voltages and generates logic ‘1’ 
or ‘0’ on its output.  If DOPA is greater than DOPB, comparator generates ‘1’, 
otherwise ‘0’. The purpose of comparator is sending commands to switcher and 
based on comparator’s output, switcher chooses between DOPA and DOPB (logical 
‘1’ will give DOPA voltage on switcher’s output and in case of logical ‘0’, DOPB 
value will appear on output of switch). Figure 25 : Differential operator (DOP) – 
DOPA (IC2D) is on the bottom and DOPB(IC2C) is upper. IC1A is comperator for 
switching between DOPA and DOPB outputs. IC3A is a switch and it switchs 
between DOPA and DOPB. 
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Figure 25: Differential operator (DOP) - DOPA(IC2D) is on the bottom and 
DOPB(IC2C) is upper. IC1A is comparator for switching between DOPA and DOPB 
outputs. IC3A is a switch and it switches between DOPA and DOPB 
4.2.1.5 Analog to Digital Conversion – ADC 
Figure 26. shows an Analogue to Digital Converter (ADC) (Figure 26., 
component: IC4 - Integrated Circuit Type : ADS8317 [28]). This component 
translates analogue voltage from switcher’s output (Figure 25, component: IC3A) 
into a stream of digital bits. Voltage followers Figure 26, components: IC1C, IC1D) 
are for constant voltage for reference voltage (Figure 26, component: IC4, pin1 
VREF) and common mode voltage (Figure 26, component: IC4, pin3  -IN). Changes 
in output voltage of voltage followers (Figure 26, components: IC1C and IC2D) has 
to be almost zero or zero to provide accurate measurements. Based on the reference 
voltage, ADC evaluates input voltage [28]. Common mode voltage is "common" to 
both positive as well as negative inputs.  
 
Digital inputs and outputs are connected to CPLD with signals CS, DOUT 
and DCLOCK. Through them CPLD and ADC communicate between each other. 
When CPLD sends command through signal CS, ADC responses with serial stream 
of 16 bits on signal DOUT.  
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Figure 26: Analog to Digital Conversion ADC with voltage followers for constant 
and stable reference and commend mode voltage 
4.2.2 Digital Part of the ParMes 
4.2.2.1 Preparing of ParMes Environment for Digital Part of ParMes: Altera 
Quartus II 
Altera Quartus II is a software environment provided by Altera[67] Figure 
27, which enables us create  solutions for all phases of FPGA (Field-Programmable 
Gate Array) and CPLD (Complex Programmable Logic Device) projects.  It offers a 
range of facilities when designing models in VHDL, Verilog HDL and  Altera 
Hardware Description Language (AHDL) [67]. With different compiling toll such as 
Analysis and Synthesis with Partition Merg, Place&Route, Assembler, TimeQuest 
TimeAnalysis, Design Assistant, EDA Netlist Writer and HardCopy Netlist 
Writerhelp helps designers in all steps of the hardware design.  
 
For each phase of ParMes hardware design, we could utilise Quartus II and 
its either graphical user interface or command-line interface.  For project simulation 
Quartus II uses another tool called ModelSim Figure 27. It [68] is a simulation 
environment for a quick debug of the root cause of design failures. Debug flow tool 
is using waveforms and graphical dataflow for designing connectivity [68].  
Waveform is used for determining failures or viewing and analysing memories. 
ModelSim is used for verifying FPGA, CPLD or ASIC project [68] through different 
waveforms and dataflow.   
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For illustrating digital parts of ParMes and drawing block diagrams of it we 
will use MS Visio 2010 have been used. This toll is provided by Microsoft and MS 
Visio 2010 is assists in creating an organization charts, data flows, a network 
diagram, or a business process. 
 
4.2.2.2 FTDI – Future Technology Devices International   
FTDI [69] is integrated circuit for USB connectivity and it bridges multiple 
communication technology (RS232, I2C, SPI, UART, etc.). In our research, we used 
FT230X[30] type from the set of FTDI integrated circuit as translator from USB to 
UART and UART to USB. It has additional role as a power supply for 3.3V.  
4.2.2.3 Complex Programmable Logic Device – CPLD 
Complex Programmable Logic Device – CPLD (Integrated Circuit type of : 
5M160ZE64C5N [29] by Altera Manufacture) is programmable device, where 
macrocells [29] are basics blocks and can preformed a multitude of logic function. It 
is essential part of ParMes, since it has three separate tasks to do: Communication 
with smart phone App, communication with Analog to Digital Convertor and to 
controlling digital logic and power consumption on the circuit (Low Battery 
Consumption – LBC). 
 
 
 
Figure 27: Left figure is User Interface of Altera Quartus II. Right figure is ModelSim 
development tool for simulations of HDLs 
 
52 The Proposal – Device and Software App for PD Drug Administration 
 
4.2.2.3.1 Low Battery Consumption – LBC 
Low battery consumption (LBC) ensures power supply to analogue section 
when measurement is required. This is important for two reasons:  
- saving battery energy while no measurement isn't requested 
- electrical circuit is limited with maximum current of 50mA and if all 
components will turn off at the same time, the current consumption will 
exceed current limitation (at power up CPLD needs 40mA and ADC needs 
20mA, currents in all other devices are insignificant). 
 
To solve this problem, ParMes is powering up in stages. At the first stage, 
CPLD powers up with consumption of 40mA and after it reaches stable and 
operation state, i.e. it consumes less current, at around 10µA. While CPLD is 
powering up, all other sections are powered down except FTDI. To power up rest of 
the components, they have to meet two conditions: 
-  CPLD has to be in stable power up state 
- Request for Measurement has to occur - stand-by state.  
While digital part of ParMes is in stand-by state, the logic in CPLD is waiting 
on falling edge on RX bus. After logic detects falling edge of the start bit, it changes 
the state of the switch (Appendix Error! Reference source not found. component 
IC8) form off to on, which starts powering up analogue part of the ParMes. However, 
LBC needs to ensure synchronization between CPLD logic and analogue part of 
ParMes due to propagation delay of powering up the analogue part of ParMes. With 
connection to that, logic start executing measurement command after 10µs of the 
received start bit and at that time analogue section is stable. When ParMes preforms 
2560 pressure measurements, LBC logic puts analogue part of ParMes back into 
power-off, deactivate switch (Appendix Error! Reference source not found. 
component IC8) and preform reset on CPLD logic until new measurement request is 
send. LBC is made from four parts Figure 28: 
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Figure 28: Block diagram for power management and controlling measurement  
 
4.2.2.3.2 Measurement Execution 
Measurement Execution of ParMes digital part connects CPLD with Analog 
to Digital Converter through signal CS, DOUT and DCLOCK. The first sample 
acquisition starts when LBC detects falling edge on the RX signal. After first 
pressure sample acquisition, the same procedure is repeated for 2559 by digital logic. 
To execute all 2560 pressure sample acquisition, it needs 10 seconds to conclude one 
measurement for symptom estimation. Sample acquisition executes every 4 
milliseconds.  
 
Figure 29: Block diagram for Measurement Execution 
4.2.2.3.3 UART Communication  
UART connection sends all captured sample acquisitions from Analog to 
Digital Converter to the master device. Signal “done” tells UART logic that the 
sample acquisition was preformed and sample data are ready for transition to the 
master device. Because the sample consists of 16 bit, the UART frame (frame 
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consists one start bit (‘0’), 8 bits of data (streams of ‘1’ and ‘0’), and stop bit (‘1’)) 
can send 8bits at once. The UART section divides the sample into two frames, each 
of them consists 8bits, consequently every separate sample acquisition is sanded in 
two frames.     
 
Figure 30: Block Diagram of the TX UART communication with smart phone App 
4.3 Developing Software Application ParMesApp 
In order show the functionality of ParMes as a device and the results of the 
measurement of Tremor and Bradykinesia in PD patients, we have developed an 
environment where ParMesApp can be generated and run on the ParMes, attached to 
a smart phone. The choice of Android environment for ParMesApp is underpinned 
with the following two reasons: 
 
1) Android has been taken by numerous smart phone manufacturers and it is 
very likely that it might overrun the number of downloads of Apps on iPhone 
[70] [71] 
2) An operating environment Android Studio [31] for creating an android App is 
user friendly.  It does not impose restrictions  on App-developers in terms of 
pre-conditions directed by Google [72].  Android studio also allows an 
efficient creation of UI, writing function in Java and C++, debugging the 
code and secures the connectivity with predefined databases.  As an 
Integrated Development Environment (IDE) it is equipped with necessary 
plug-ins which makes it a cutting edge for any prosperous IDE.  
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The design and development of the ParMesApp have had two prerequisites 
from the software development point of view.  They are itemized in bullets a) and b) 
below:  
a) An overall software architecture (SA) is needed for creating an environment 
where ParMesApp will reside. The SA must be generated from the 
functionality, which is expected to be delivered through ParMesApp.  
However, in a highly interactive and mobile environment, User Interfaces 
(UI) usually govern the logic of the manipulation of ParMesApp by a 
particular PD patient.  Therefore, the functionalities depicted in the SA must 
be accompanied with a set of UI which illustrate the way ParMesApp works.  
This abstract model of the SA, must be created through either UML diagrams 
or software patterns like MVC [73].  It should be a generic solution in order 
to absorb all possible changes we may have in future when using Android 
operating system.  It should also accommodate the way the calculations of 
Tremor/Bradykinesia/PD drug administration is performed and possibly 
changed in future. 
b) Software components defined through the ParMesApp SA must be 
deployable within the Android Studio.  Therefore, abstract SA components 
become technology specific in order to have a successful deployment of 
ParMesApp.  It is assumed, particularly if MVC pattern is used, that SA 
strictly distinguishes between UI defined at the front end of ParMesApp and 
repositories of data, generated by sensors within ParMes, which are used for 
calculating drug administration for PD patients.  
 
It is important to note that this ParMesApp may have two different types of 
repositories.  One should be a pool of sensor-generated data by ParMes, which 
contains measurement of a PD patient's Tremor and Bradykinesia.  This data does 
not have to persistent. The other type of data is a traditional database repository, i.e. 
persistent data, which may store demographic and clinical data relevant to a 
particular PD patient.  The development of the later is outside the scope of this 
research.  However, access to persistent data must be guaranteed through the SA 
offered for ParMesApp.  
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In the next following subsections, the design of SA for ParMesApp has been 
illustrated.   
 
In section 4.3.1 we describe the preparation environment for creating 
ParMesApp in Android Studio.  In the section which follows we develop an abstract 
model of ParMesApp in the form of its SA and in section 4.3.2 we used Android 
technology specific components.  We also show the level of computation which may 
exist in order to manipulate the results of measuring the pressure of PD patients on 
the screen of a smart phone, using ParMes.  The results of running ParMesApp is 
shown through a set of user interfaces.   
4.3.1 Android Studio for Developing ParMesApp 
Android Studio [74] is an Integrated Development Environment (IDE) which 
allows the development of Android Application.  It is based on IntelliJ IDEA [74].  It 
allows multiple Android Application Package (APK) [74] file generation, and 
provides a rich layout editor, with the support for drag and drop theme editing.  The 
foundation of Android Studio is Gradle Build System which runs as an integrated 
tool from the Android Studio and independently from the command line.  It can:  
 Customize, configure and extend the development process, 
 Create multi APKs for an app with different features, using the same project 
and modules,  
 Reuse code and resources across source sets. 
 
Under Gradle Scripts we keep developed files and each App module contains 
the following three elements: manifests (Manifest file), Java (Source Code file) and 
Res (Resource file) [74].  Android Studio can be manipulated through either 
graphical user interface or command-line interface.  
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Figure 31: Android Studio development environment for developing Android Apps 
4.3.2 Software Architectures for ParMesApp  
A prerequisite for developing an abstract model of ParMesApp, in the format 
of Software Architectural solution, is a set of UML diagrams which 
1. capture the functionality of ParMesApp in use case model and 
2. define the main abstractions of ParMesApp in the format of Objects, Classes, 
Attributes and Operations, which in turn would produce a class diagram for 
ParMesApp.  
 
However, by starting designing User Interfaces (UI) we could pinpoint 
relatively quickly what would constitute the required functionality of ParMesApp.  
Figure 32 below, which is self-explanatory shows exactly how these UI appear in the 
course of running the solution, i.e. ParMesApp. 
 
In the first UI, only two buttons available: upper button “TREMOR” is 
dedicated for measuring PD Tremor, while lower button “BRADYKINESIA” 
measures Bradykinesia.  When a PD patient chooses which type of measurement is 
going to be performed, the ParMesApp will lead the patient through the measurement 
procedure.  When the measurement is completed, ParMesApp will show result which 
is expected to be “Severity of PD symptoms” and “Recommended drug 
administration”.  
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Figure 32: UI flows of ParMesApp 
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4.3.2.1 UML Use Case Models and User Interfaces 
The use case model, given in Figure 33 is relatively simple: it shows that a 
PD patient may be involved in running two distinctive functionalities: measuring 
Tremor or measuring Bradykinesia.   
 
Figure 33:Use Case Model for ParMesApp 
 
 
Figure 34: A Detailed UI for initiating ParMesApp 
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Figure 35: A Detailed UI for Performing Measurements of TREMOR 
 
Figure 36: A Detailed UI for Performing Measurements of Bradykinesia 
 
Figure 37: Results: Severity of Symptoms and suggested Drug Administration 
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4.3.2.2 UML Sequence Diagrams and ParMesApp Software Architectures 
Figure 38 and Figure 39 show abstractions derived from the semantics 
presented in the previous section and include objects in both sequence diagrams 
which are User Interface Objects for using the ParMesApp, (yellow), computational 
and control objects (red and green) and data objects (Blue).  
 
In Figure 38., we can see that the application ParMesApp is controlled by an 
object which prepares programs and data for measuring TREMOR and 
consequently, we will need FFT (Fast Fourier Transform), for conversion a 
measured signal from its time domain to frequency domain and perform the 
calculation of the drug the administration in that moment.  The data which is needed 
for performing these two functions within the ParMesApp is 
 generated by sensors in ParMes device (SGD stands for Sensor Generated 
Data) and 
 available in persistent repositories such as Databases, held at Healthcare 
institutions and showing PD patient clinical and demographic data 
 
Messages passed between these objects are self-explanatory and a sample of 
them in Figure 38 does not have to be the only solution we may have for this 
application. For example, Dosage Calculation object may be sent a message by 
Prepare for Measurement TREMOR object and not necessarily by FFT object, as 
shown in the Figure 38.  This can be left for an individual developer and Healthcare 
Professional to decide upon the control of main functionalities in ParMesApp. 
 
The difference between computational and control objects in the diagram on 
Figure 38 and Figure 39. is evident and also self-explanatory: Prepare for 
Measurement TREMOR object (red) control the application ParMesApp and FFT 
and Dosage Calculation (green) perform computations where data is retrieved, 
manipulated, computed and displayed. 
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Figure 38: A Sequence Diagram for Measure Tremor Use Case 
 
Figure 39: A Sequence Diagram for Measure Bradykinesia Use Case 
 
A very similar rationale is behind the semantics stored in Figure 39.  The only 
difference is that in this case we have sensor generated data relevant for Bradykinesia 
and one of the computational objects R&M Time (Response and Measurement Time) 
calculates user’s response and movement time from received pressure measurements.   
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The synthesis of these two Figure 38 and Figure 39 is given in the format of 
the Model-View-Controller (MVC) pattern for the ParMesApp, which in turn can 
play the role of the Software Architectural solution for the application. The MVC 
pattern appears naturally, because the sequence diagrams supply a set of different 
types of objects: User interfaces UI (VIEW), computational and control objects 
(CONTROLLER) and objects. which contain data (MODEL). They all which 
naturally build MVC patterns.  Furthermore, Figure 40. shows that if we 
a) Create software components from classes of our abstract model, which have 
resulted from the conceptualisation of objects in the sequences diagrams and 
b) Group software components into layers if they originate din objects of the 
same type, 
   
We can automatically create an MVC pattern which will play a role of 
software architectural (SA) solution for ParMesApp. This model is deployable in 
many component based operating environments which are underpinned with 
component technologies [75], [76] Android applications use plug-ins which can 
deploy the architectural solution from Figure 40. within the Android Studio.  
 
It is important to note that all computations, which need data, will be 
performed after retrieving them: it can either be sensor generated data from ParMes 
or persistently stored data, about PD patients. This puts forward the main 
characteristics of this software architectural solution: all components shown in 
Figure 40. might be located on different nodes of any computer network, which do 
not imply that computations in ParMesApp are done upon data, which is solely 
generated by ParMesApp [77].  The solution consequently allows data sharing and 
makes provisions for flexibilities in case we change the way we digitalize analogue 
signals or calculate recommended dosage of medications if advances in research on 
treatments of PD patience would require to change this particular algorithm.   
 
Finally, sensor generated data may not be important to store and keep it as 
historical data, i.e. it might not be advisable to make it persistent.  What is important 
here is to make decision on the drug administration persistent and encourage frequent 
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measurements of Tremor and Bradykinesia in order to minimize errors when 
administering drugs.  
 
 
Figure 40:UML diagram 
 
Figure 40 carries on with the conventions of the role of its components as we 
find in sequence diagrams and types of objects they discover.  Therefore, UI are in 
yellow, computation which control the ParMesApp are in red, calculations of dosage 
and transformation of analog signals to digital and R&M time are in green and data 
repositories are in blue.  A strict division between UI, computations and Data has 
been achieved. This will make the SA solution form Figure 40 deployable in Android 
and reusable in any other IDE. 
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5 Deployment of the Solution 
 
This chapter illustrates the way of deploying an architectural solution for 
ParMesApp which has been delivered in Chapter 4.  However, it is important to note 
that the SA solution for ParMesApp incorporates both a hardware part of the solution 
(because the transformation from the analogue to digital data while measure the 
pressure of PD fingers has been done by the ParMesApp) and its SA specific 
components. Therefore, in spite of having two parts of the proposals for solutions in 
this research: hardware and software development, the results can be shown only by 
looking at the deployment of the application software.   
 
We have not found in the available published work any similar solution, 
which is deployed within an Android environment, and uses SA components based 
on the MVC pattern in order to perform ANY TYPE of computations you may have 
when combining hardware and software development at the same time.  Therefore, 
this chapter should be read in conjunction to sections 4.1 and 4.2 form Chapter 4.  
Consequently, only the deployment of the SA from Figure 40 can be described in this 
chapter. 
5.1 Deployment of SA Components for ParMesApp 
The deployment of ParMesApp software architectural model given in Figure 
40 is shown in Figure 41, which uses J2E component technology [32], as an 
illustration, and therefore shows only technology specific components.  One of the 
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most important parts of this deployment is a selection of software code which we 
may place within these technology specific component.  They require a specific IDE, 
such as NetBeans and Eclipse, in order to create UI, computations and access to data 
repositories as specified in the SA form the previous chapter.  
 
 
Figure 41:Deployment of UML diagram 
5.1.1 Computations for ParMesApp 
Equations which are mentioned in chapter 4.1 ( Estimating Symptoms of PD 
and Drug Administration ) were used in ParMesApp as the following software 
routines: 
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- Equation 14 – 17 which are generated for estimating tremor severity and are 
illustrated as FFT.SessionBean, which is a technology specific software 
component.  
-  Equations 18 and 19, which are in object R&MTIME.SessionBean in the 
Figure 41.  
- Equations 23 – 25 are stored in DosageCalculation.Sessionbean.  
5.1.2 Results of Running ParMesApp 
It is important to note that the coding of ParMesApp, available in appendices, 
has been a part of the IDE and Android Studio and we have to be looked at them in 
these contests. Furthermore, these calculations are stored within the SA solution in 
Figure 40 and with the help of JEE technologies they can be represented though 
technology specific components in Figure 41. The reader should take into account 
that these computations cannot be examined in isolation without taking into account 
the SA model and the deployments of its layered software components in an IDE 
environment. It is also important to emphasise that the SA form Figure 40 is reusable 
and can be used in cases if we change the way calculations are performed. 
 
Obviously, it is expected that the reader is familiar with the role and types of 
IDEs, the role of   software components in SA solutions and the impact of 
technology selection for their deployment, which is illustrated finally in Figure 41. 
The power of the MCV pattern is obvious and the separation from data presented in 
this App and calculations used to generate results is essential. Figure 41 summarises 
the results of this research: It is feasible to create an Android App, which takes the 
measurement of the severity of PD symptoms and recommends the best possible 
medicine for a PD patient, at the moment when the measurements had been taken. 
 
In Figure 42 we show UI which house the final results of running 
ParMesApp.  Their content is self-explanatory. 
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Figure 42: Left UI presents results for Tremor, while right figure shows to user 
results for Bradykinesia 
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6 Conclusion 
This thesis demonstrates that it is feasible to build an Android App for more 
precise and personalized drug administration for PD patients.  
 
The software development, which can assist in creating computations 
relevant to the drug administration, is reusable and based on creating a software 
architecture first, in order to achieve the thesis objectives, and address the main 
motivation of the research outlined in (i) and (ii) from the Introduction.  Therefore 
the proposed software solution ParMesApp will be adaptable and reusable for any 
future changes in the way we compute or develop algorithms for the PD drug 
administration, which is very important when evaluating the output of this research.  
 
The issue of creating a separate mobile device for the measurements of the 
figure pressure of a PD patient has had a different outcome. It was feasible to design 
and develop such a device during the course of this research. However, it was 
extremely difficult to place the computations for drug administration without having 
a smart phone and its operating environment available. Smart phones give much 
more power and opportunities for creating intelligent software solution compared to 
any sophisticated device we may develop for the purpose of measuring pressures of 
fingers of PD patients.  Consequently the part of the proposal in this research is to 
have a new developed gadget ParMes as a “slave” to any Android smart phone in 
order to make decision making on drug administration feasible. It should also be 
accessible and taken by patients, through attractive UI and ParMesApp ready to run 
on smart phones, which PD patients may have already had. 
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The contribution to knowledge and practice in this research is multiple: 
 We created a device ParMes which is specifically designed to measure the 
severity of symptoms in PD patients 
 ParMes can be attached to any smart phone and therefore we can use the power 
of their operating environments to advice on the best possible drug 
administration.  In other words, PerMes does not have to carry out any 
computation. 
 We modified existing calculations for drug administration to fit our needs when 
using ParMes (Section 4.1) 
 We created a reusable SA for ParMesApp which can accommodate any changes 
in the way the drug administration has been calculated and UIs have been 
designed (Section 4.3).  We have also allowed for changes in accessing persistent 
data repositories, which can enrich our ParMesApp and have PD patient’s 
demographic and clinical data available when he/she runs the App. 
 Our ParMesApp delivers an advice on the PD drug administration at the moment 
when the measurement of PD symptoms are carried out. Therefore it personalizes 
drug administration and makes it precise to fit the needs of the patient at the 
moment when the patient needs it. It can be run many times per day when the 
patient feels that his/her symptoms changed.  
6.1 Achieving Research Objectives 
In this research, developments have been made towards: 
-  Understanding PD and disabilities of PD patients 
-  Understanding and paving the way towards improving PD treatments, by 
paying attention to their side effect and optimizations of treatments 
-  Designing a device which can measure physical behaviour of a patient and 
their symptoms and Android App which can calculate their severity and 
advice on the best possible drug administration 
 
This project has been initially focused on designing the device ParMes, which 
will measure applied pressure of PD patient’s muscles.  This has been finalised on 
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time because our first O1, which has been met in Chapter 3 highlighted where the 
problem is and how it should be approached.  We have concluded that PD treatments 
at some stage make more harm than good and the developed device ParMes might be 
able to make significant changes. Our second object has also been met in Chapter 3. 
The third and fourth objective have been meet in Chapter 4.  The device which 
measure applied pressure of PD fingers in order to estimate the severity of the PD 
symptoms for Tremor or Bradykinesia has been designed and developed. The 
software application has also been designed, but through its software architectural 
solution and deployed in Chapter 5 as an Android App, which was implemented in 
the fashion of the MVC pattern.  It makes a strict distinction between presentations. 
i.e. UI in this solution and computations stored within the App in order to 
recommend the best possible administration of medicine.   
 
Out fifth objective requires more debate and discussions within the scientific 
and healthcare communities, which is outside the scope of this thesis. It has to be 
debated if the future of pervasive healthcare is in (a) creating more mobile devices 
which are supposed to exhibit intelligent computational power or (b) the use of smart 
phones which carry a powerful Android operational environments in order to create 
more intelligent software solutions for the same problem.  At the moment it is very 
difficult to answer this question, i.e. more debate is needed for deciding if either (a) 
or (b) is the way forward. 
6.2 Place for Improvement 
There are a few issues, which appeared during the course of this research and 
which need attention. 
 
During development, simulation and contraction, we have experienced 
different technical problems:  
- incorrect measurements can be the results of the changing temperature 
(properties of components can vary because of because of temperature), of 
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the noise from the antennas (WiFi, NFC, GMS), of the factually incorrect 
elements 
-  power consumption of ParMes contributes to shorter battery life of self-
phone although ParMes is designed to consume bit of energy. Problem will 
be solved with ASIC integrated circuit  
-  size of ParMes might be a problem: ParMes is big, due to components it 
comprises. In future an ASIC integrated circuit should be designed. 
-  The performance of the proposed solution: we cannot change any parameters 
within the model and the duration of the measurements are always the same. 
We used CPLD which doesn't have big number of microcells and due to that 
we could not implement more digital logic into CPLD. 
- When calculating parameters, any mistake in the measurements might end up 
with inability to calculate correct parameters for severity of the PD 
- Position of the sensors are not optimal, due to uneven rear side surface of the 
smart phone: some sensors will perform better connection with these surface 
then others 
-  Price of the device: all elements and production of ParMes costs around 
500kr. (cost are calculated based on retailer prices). 
6.3 Future Work 
To reduce the cost and size of ParMes we should produce a dedicated 
integrated circuit ASIC, which will combine all the components on ParMes except 
sensors into one small Integrated circuit. This will solve big part of the problems 
described in Chapter 6.2 Place for Improvement. To develop ASIC and drivers for 
Android OS, we will need around 1800 human hour and if 1 human hour is 700kr, 
development of the ASIC will cost us 1.26 million kron. When development will be 
concluded manufacturing will take its place. For production of 10000 ASICs pieces, 
the ASIC manufacturer will charge us 1.04 million Kron. Parallel with that we need 
develop user friendly App which will have knowledge about communication 
between patients, physicians, database and ParMes device. For development of App 
we predicted 500 human hours with price of 350000 Kron. Without self-phone case 
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ParMes device doesn't have any meaning and to have one the final product which 
will be plug and play we need develop case which will be appealing visually and it 
has to be practical. This will cost as additional 500000 Krons for 10000 pieces. With 
that conclusion, if we want to operate without losses we have to charge 315 Krons by 
piece.  
 
This device can be used in other diseases or in everyday life of healthy 
people, for tracking their behaviour, helping them with everyday tasks, for improving 
their wellbeing and restrain user from dangerous activities. For instance,  
- If a user is under the stress, ParMes can identify a stress from pressure on the 
screen.  
- Another application is in safe driving area. If a person was drinking alcohol 
before he wishes to drive he or she can find out through ParMes and 
ParMesApp tests of her or his capacity for driving through measurements of 
Reaction time. This App can alert user about her or his physical properties 
and suitability for driving a car. 
 
There is a small step between the result of this research and its 
commercialization.  However, any commercialization would require to input more 
resources and time/money towards the development of an uniform Android App 
which might have multiple uses in future, particularly in the field of drug 
administration.  However, before we pave the way towards new solutions for the PD 
patient’s drug administration, which has been propose in this thesis, objective 5 must 
be revisited and more public debate should be conducted in order to pave the way 
forward and decide what the rule of future mobile gadget in pervasive healthcare is.   
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Figure 43: Model of the circuit - Analog part of the ParMes 
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Figure 44: Model of the circuit - Digital Part of the ParMes 
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Figure 45: Circuit layout of ParMes Device. Palce of the components and 
connection between them 
